NZ722290B2 - Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy - Google Patents

Abstract

compound of formula (Ie) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection caused by RNA viral infection.

Description

(12) Granted patent specificaon (19) NZ (11) 722290 (13) B2 (47) Publicaon date: 2021.12.24 (54) PYRAZOLO[1,5-A]PYRIMIDINAMINE DERIVATIVES USEFUL IN THERAPY (51) Internaonal Patent ficaon(s): A61K 31/519 A61P 31/12 (22) Filing date: (73) Owner(s): 1.21 r AB (23) te specificaon filing date: (74) Contact: 2015.01.21 HENRY HUGHES IP LIMITED (30) Internaonal Priority Data: (72) Inventor(s): EP 14152202.9 2014.01.22 WESTMAN, Jacob (86) Internaonal Applicaon No.: (87) Internaonal Publicaon number: WO/2015/110491 (57) Abstract: A compound of formula (Ie) or a pharmaceucally acceptable salt thereof, useful in therapy, in parcular in the treatment of a viral infecon caused by RNA viral infecon.

NZ 722290 B2 PYRAZOLO[1,5-A]PYRIMIDINAMINE DERIVATIVES USEFUL IN THERAPY FIELD OF THE INVENTION The present invention relates generally to compounds having usefillness in y, in particular in the ent of conditions caused by n viruses, such as diabetes, cancer, neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis.

More particularly the invention relates to pyrazolo[1,5-a]pyrimidinamine derivatives for use in therapy.

BACKGROUND OF THE INVENTION Pyrazolo[1,5-a]pyrimidine is a commonly used scaffold in medicinal chemistry and derivatives thereof are known for their potent utility as analgesics, iazepine receptor antagonists, angiotensin II receptor nists, angiogenesis inhibitors, anti-inflammatory agents, neuropeptide Y receptor antagonists, COX2- inhibitor and corticotrophin-releasing hormone receptor type 1 antagonists and as CHK1 inhibitors (e.g. Mayo et al (Adv. Synth.

Catal. 2003, 345, 620-624; Tellew et al g. Med. Chem. Lett. 2010, 20, 264); Chen et al (Bioorg. Med. Chem. Lett. 2004, 14, 3669-3673); Labroli et al (Bioorg. Med.

Chem. Lett. 2011, 21, 471-474); Griffith et al (Bioorg. Med. Chem. Lett. 2011, 21, 2641- 2645); Gilligan et al, (J. Med. Chem. 2009, 52, 083); He et al. (US Patent No. 6,313,124 B1); and Wren et al. (WO 86040).

The scaffold has also been described in phosphatidylinositol 4-kinase (PI4K) inhibitors.

Bianco et al (PLoS Pathogens, 2012, 8(3), 1-17) and LaMarche et al (Antimicr. Agents and Chemother. 2012, 56(10), 5149-5156) have shown that PI4K is important for hepatitis C Virus (HCV) replication and Yang et al (J. Biol. Chem. 2012, 287(11), 8547-8467) have shown the same for coronavirus. McLeod et al (ACS Med. Chem. Lett. 2013, 4(7), 585-589) and van der Schaar et al (Antimicrobial Agents Chemother. 2013, 57(10), 4971-4981) have shown some imidazopyrazines derivatives inhibiting PI4K that are potent antiVirals s picomaVirus.

Gudmundsson et al g. Med. Chem. Lett. 2009, 19, 5689-5692) have disclosed some 3- arylpyrazolo[1,5-a]pyrimidines with potent activity against herpesviruses.

Hwang et al (Bioorg. Med. Chem. Lett. 2012, 22, 7297-7301) have described 3- arylpyrazolo[1,5-a]pyrimidines as PI4K inhibitors that have CV effects.

Décor et al (Bioorg Med Chem Lett. 2013, 23, 3841-7) have also shown that PI4K is important for enterovirus replication. However, they have also shown that PI4K inhibitors (non 3-arylpyrazolo[1,5-a]pyrimidines) and the 3-arylpyrazolo[1,5-a]pyrimidine 3-(3,4- dimethoxyphenyl)-2,5-dimethyl-N-(2-morpholinoethyl)pyrazolo[1,5-a]pyrimidinamine (called THEV1) when tested in-vivo induced mortality in mice, which raised doubts on the safety of inhibiting PI4K.

SUMMARY OF THE ION In a first aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (Ie) or a pharmaceutically acceptable salt thereof, wherein R1 is methyl; each R2 is methoxy; R3 is methyl; m is an integer of from 0 to 2; each R4 is independently ed from C1-C6 alkyl, R12O, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, R21C(O)-, (R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl; R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or two R4 attached to adjacent atoms of ring B form, er with the atoms to which they are attached, a 5- or 6-membered heterocyclic or carbocyclic ring, or a benzene ring; and ring B is 5- or 6-membered heteroaryl or phenyl.

In a second aspect, the invention provides a compound of formula (Ie) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions thereof R1 is methyl, each R2 is methoxy; R3 is methyl; m is an integer of from 0 to 2; each R4 is independently selected from C1-C6 alkyl, R12O, halogen, NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, )-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is optionally tuted by one or more F; or two R4 attached to adjacent atoms of ring B form, together with the atoms to which they are attached, a 5- or 6-membered heterocyclic or carbocyclic ring, or a benzene ring; ring B is 5- or 6-membered heteroaryl or phenyl; ed that the compound is not: N-[(4-chlorophenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo[1,5-a]pyrimidinamine, N-(1,3-benzodioxolylmethyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-fluorophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, or N-benzyl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine.

Further provided is the use of the compositions and compounds described above, in the manufacture of a medicament for the treatment of a viral infection, e.g. an RNA viral infection.

In a further , the t invention provides for the use of a compound of formula (Ie) or a pharmaceutically acceptable salt thereof, n R1 is methyl, each R2 is methoxy; R3 is methyl; m is an integer of from 0 to 2; each R4 is independently selected from C1-C6 alkyl, R12O, n, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, R21C(O)-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are independently ed from C1-6 alkyl; any alkyl is ally substituted by one or more F; or two R4 attached to adjacent atoms of ring B form, er with the atoms to which they are ed, a 5- or 6-membered heterocyclic or carbocyclic ring, or a benzene ring; ring B is 5- or 6-membered heteroaryl or phenyl; in the manufacture of a medicament for the treatment of an RNA viral infection, e.g. a picornaviral infection.

The invention is described further in r terms below. Certain aspects and/or embodiment are not the subject of the present invention and are thus described for completeness.

Thus broadly provided is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein W is ; p is an integer of from 0 to 3; R1 is H or C1-C6 alkyl; ring A is phenyl or 5- or 6-membered aryl; when ring A is phenyl, said phenyl is not substituted in ortho position; each R2 is independently selected from C1-C6 alkyl, R5O-, R6R7NC(O)-, R9C(O)N(R8)-, R10OC(O)-, R11C(O)O-, and halogen; R5, R6, R7 and R8 are independently selected from H and C1-C6 alkyl; R9, R10 and R11 are ndently selected from C1-6 alkyl; any alkyl is optionally tuted by one or more F; or two R2 attached to adjacent carbon atoms together form a methylenedioxy or ethylenedioxy biradical; R3 is C1-C6 alkyl; and m is an integer of from 0 to 2; each R4 is independently selected from C1-C6 alkyl, R12O, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, R21C(O)-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are ndently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or two R4 attached to nt atoms of ring B form, er with the atoms to which they are attached, a 5- or 6-membered cyclic or carbocyclic ring; ring B is 5- or 6-membered saturated or unsaturated carbocyclyl, 5- or 6-membered heteroaryl, or phenyl; for use in therapy, provided that the compound is not: 3-(4-chlorophenyl)-N-(4-methoxyphenyl)methylpyrazolo[1,5-a]pyrimidinamine, N-(cyclohexylmethyl)-2,5-dimethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, 2,5-dimethyl-N-phenyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, N-benzyl-2,5-dimethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, or 2,5-dimethyl-N-phenethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine.

Some of the compounds according to formula (I) as defined herein above are novel. Thus, also provided are novel compounds of formula (Id) or a pharmaceutically acceptable salt thereof, wherein W is ; R1 is H or C1-C6 alkyl, each R2 is independently selected from C1-C6 alkyl, R5O-, R6R7NC(O)-, R9C(O)N(R8)-, R10OC(O)-, R11C(O)O-, and halogen; R5, R6, R7 and R8 are independently selected from H and C1-C6 alkyl; R9, R10 and R11 are independently selected from C1-6 alkyl; any alkyl is optionally tuted by one or more F; or two R2 together form a methylenedioxy or ethylenedioxy biradical; R3 is C1-C6 alkyl; m is an integer of from 0 to 2; each R4 is independently selected from C1-C6 alkyl, R12O, n, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, )2-, R21C(O)-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or two R4 ed to adjacent atoms of ring B form, together with the atoms to which they are attached, a 5- or ered heterocyclic or carbocyclic ring; ring B is 5- or 6-membered heteroaryl, or phenyl; provided that the compound is not: N-[(4-chlorophenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, N-[2-(4-chlorophenyl)ethyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(3-phenylpropyl)pyrazolo[1,5-a]pyrimidin amine, N-(1,3-benzodioxolylmethyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-fluorophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-phenylpropyl)pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-N-[2-(2,4-dimethoxyphenyl)ethyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, N-benzyl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, N-(4-bromophenyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, hlorophenyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-(4-methoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(m-tolyl)pyrazolo[1,5-a]pyrimidinamine, N-(3-chlorophenyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-N-(3,4-dimethylphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-N-(4-fluorophenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-N-(4-ethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, N-(3-chloromethyl-phenyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-(3,5-dimethylphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, (followed by page 9A) -dimethoxyphenyl)-2,5-dimethyl-N-phenyl-pyrazolo[1,5-a]pyrimidinamine, N-[4-[[3-(3,4-dimethoxy phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]phenyl]acetamide N-(3,4-dichlorophenyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-N-(4-isopropylphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-N-(3-methoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine 3-(3,4-dimethoxyphenyl)-N-(4-ethylphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, N-(4-butylphenyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, N-(3,5-dichlorophenyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin amine.

Still another aspect is a novel compound of formula (Ih) or a pharmaceutically able salt thereof, wherein p is an integer of from 1 to 3; R1 is H or C1-C6 alkyl; Z is N or CR2 each R2 is independently ed from C1-C6 alkyl, R5O-, R6R7NC(O)-, R9C(O)N(R8)-, R10OC(O)-, R11C(O)O-, and halogen; R5, R6, R7 and R8 are independently selected from H and C1-C6 alkyl; R9, R10 and R11 are independently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or two R2 together form a methylenedioxy or ethylenedioxy biradical; no R2 is attached in ortho position on the phenyl ring; R3 is C1-C6 alkyl; m is an integer of from 0 to 2; (followed by page 9B) each R4 is independently selected from C1-C6 alkyl, R12O, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, )-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or two R4 attached to adjacent atoms of ring B form, together with the atoms to which they are attached, a 5- or 6-membered heterocyclic or yclic ring; ring B is 5- or 6-membered heteroaryl, or phenyl; ed that the nd is not: N-benzyl-2,5-dimethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, 3-(4-methoxyphenyl)-2,5-dimethyl-N-(pyridinylmethyl)pyrazolo[1,5-a]pyrimidin amine, 3-(4-methoxyphenyl)-2,5-dimethyl-N-(pyridinylmethyl)pyrazolo[1,5-a]pyrimidin amine, N-[(4-chlorophenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo[1,5-a]pyrimidinamine, -benzodioxolylmethyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-fluorophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, N-benzyl(4-fluorophenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, N-benzyl(4-fluorophenyl)methyl-pyrazolo[1,5-a]pyrimidinamine, N-benzyl(4-chlorophenyl)methyl-pyrazolo[1,5-a]pyrimidinamine, 2,5-dimethyl(p-tolyl)-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 2,5-dimethyl(p-tolyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, 3-(4-fluorophenyl)-2,5-dimethyl-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, (followed by page 9C) 3-(4-fluorophenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, N-benzyl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, 3-(4-chlorophenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(4-chlorophenyl)-2,5-dimethyl-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(4-methoxyphenyl)-2,5-dimethyl-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, ethoxyphenyl)-2,5-dimethyl-N-(4-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine.

Another aspect is a compound of a (Id) or of formula (Ih) for use in therapy.

Another aspect is a compound of formula (I), as defined herein, or a compound of formula (Id), or a compound of formula (Ih), for use in the treatment of a viral ion, e.g. an RNA viral infection.

Another aspect is a compound of formula (I) or a pharmaceutically able salt thereof, wherein W is ; p is an integer of from 0 to 3, R1 is H or C1-C6 alkyl, ring A is phenyl or 5- or 6-membered heteroaryl; when ring A is phenyl, said phenyl is not substituted in ortho position; each R2 is independently selected from C1-C6 alkyl, R5O-, R6R7NC(O)-, R9C(O)N(R8)-, R10OC(O)-, R11C(O)O-, and halogen; R5, R6, R7 and R8 are independently selected from H and C1-C6 alkyl; R9, R10 and R11 are ndently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or wed by page 9D) two R2 attached to adjacent carbon atoms together form a methylenedioxy or ethylenedioxy biradical; R3 is C1-C6 alkyl; m is an integer of from 0 to 2; each R4 is independently selected from C1-C6 alkyl, R12O, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, R21C(O)-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or two R4 ed to adjacent atoms of ring B form, together with the atoms to which they are attached, a 5- or 6-membered heterocyclic or carbocyclic ring, or a benzene ring; ring B is 5- or 6-membered saturated or unsaturated carbocyclyl, 5- or 6-membered heteroaryl, or phenyl; for use in the treatment of a viral infection, provided that the compound is not: N-(cyclohexylmethyl)-2,5-dimethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, 2,5-dimethyl-N-phenyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, N-benzyl-2,5-dimethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, or 2,5-dimethyl-N-phenethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine.

In some embodiments, the viral ion is a non-enveloped single-stranded (+) RNA viral infection.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a m showing the number of surviving animals as a function of the number of days after ions with Coxsackie B3 virus, in mice treated with the nd of Ex. 9, 200 mg/kg once daily per orally starting on day 1 (group 1) or on day 3 (group 2), and in mice treated with vehicle only (0.4% Tween 80, 2% glycerol and 15% β-hydroxypropyl extrin).

DETAILED DESCRIPTION OF THE INVENTION (followed by page 10) “Pharmaceutically acceptable” means being useful in preparing a pharmaceutical composition that is generally safe, xic and r biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.

“Treatment” as used herein includes prophylaxis of the named disorder or condition, or amelioration or ation of the disorder once it has been established.

“An ive amount” refers to an amount of a compound that confers a therapeutic effect on the treated t. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).

Unless otherwise stated or indicated, the term “C1-6 alkyl” denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said C1-6 alkyl e methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branchedchain pentyl and hexyl.

The term “C1-C6 hydroxyalkyl” refers to a C1-C6 alkyl substituted with one OH. An example of a C1-C6 hydroxyalkyl is hydroxymethyl: -CH2OH.

Unless otherwise stated or indicated, the term “halogen” (or “halo”) refers to fluorine (F), chlorine (Cl), or bromine (Br).

A moiety of the type R´R´´NC(O)- is a moiety of formula W0 2015/110491 10 A moiety ofthe type RHC(O)N(RV)- is a moiety of formula R”\n/N>; A moiety ofthe type )- is a moiety of formula Rrom)‘ A moiety ofthe type R'C(O)O- is a moiety of formula REC}; A moiety ofthe type RVS(O)2- is a moiety of formula R’\ ,,o it“.

A moiety ofthe type RVS(O)2N(H)- is a moiety of formula R’\at“);,,o A moiety ofthe type NHZS(O)2- is a moiety of formula H2N\ ,,o :x A moiety ofthe type RVC(O)- is a moiety of formula RV.O W0 2015/110491 11 A moiety ofthe type N(Rr)(R' ')- is a moiety of formula R'I/Ny.

As used herein, the term “carbocyclic ring” refers to a saturated or unsaturated (e.g. monounsaturated or diunsaturated), non-aromatic cyclic moiety containing only carbon atoms in the ring, such as hexyl or hexenyl.

The term “heterocyclic ring” refers to a saturated or unsaturated, non-aromatic cyclic moiety ning not only carbon atoms, but also at least one other atom in the ring, e.g. selected from nitrogen (N), sulphur (S) and oxygen (0), in particular N and 0; such as piperidinyl, or l,2,3,4-tetrahydropyridinyl. Other examples of heterocyclyl include linyl, pyrrolidinyl, piperazinyl, tetrahydrothienyl, and tetrahydrofuryl.

The term “heteroaryl” refers to an aromatic ring containing at least one ring atom, such as fiaryl, isoxazolyl, isothiazolyl, olyl, pyridyl, pyrrolyl, pyrazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxadiazolyl, oxazolyl, thienyl, thiadiazolyl, thiazolyl, triazolyl, and tetrazolyl.

The term tic”, as used herein, refers to an unsaturated cyclic moiety that has an aromatic character, While the term “non-aromatic”, as used herein, refers to a cyclic moiety, that may be saturated or unsaturated, e.g. polyunsaturated, but that does not have an ic character.

The term “phenyl” refers to a moiety of formula C6H5-, i.e.; 9 The term “benzyl” refers to a moiety of formula C6H5CH2-, i.e.; The term “phenylethyl” refers to a moiety of formula C6H5C2H4-, i.e.: W0 2015/110491 12 A lenedioxy biradical” is a biradical of formula -OCHzO-.

An “ethylenedioxy biradical” is a biradical of formula -OCH2CHzO-.

“Treatment” as used herein includes prophylaxis of the named disorder or condition, or amelioration or elimination (i.e. cure) of the disorder once it has been established.

An “effective amount” refers to an amount of a compound that confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker, e.g. no measurable virus titre in a biological sample from the treated t) or subjective (i.e., subject gives an indication of or feels an effect).

A “non-enveloped single-stranded (+) RNA viral infection” refers to an infection with a non- enveloped single-stranded (+) RNA virus.

A nveloped virus” is a virus lacking viral envelope.

A “single-stranded (+) RNA virus” is a virus having genetic material which is single-stranded RNA and which RNA can be immediately translated to viral protein by the cell infected by the virus.

The term “mammal” refers to a human or any mammalian animal, e.g. a primate, a farm animal, a pet , or a laboratory animal. Examples of such animals are monkeys, cows, sheep, goats, horses, pigs, dogs, cats, rabbits, mice, rats etc. ably, the mammal is a human. In some embodiments, r, the mammal is an animal, e.g. a farm animal, such as a cow, sheep, goat, horse, or pigs. In some other embodiments, the animal is a pet, e.g. a dog, a cat or a rabbit.

The term “excipient” refers to pharmaceutically acceptable als, such as known to those of ordinary skill in the art of pharmacy to aid the stration of the medicinal agent. It a compound that is useful in preparing a pharmaceutical composition, generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable W0 2015/110491 13 for veterinary use as well as human pharmaceutical use. Exemplary excipients include binders, surfactants, diluents, disintegrants, antiadherents, and lubricants.

Herein below, any reference to a compound of formula (I) or a nd of the invention, should be ued as referring to a compound for use according to the invention, as defined in the claims.

In a compound of formula (I) R2 )p (R4)m N / / H (I) W—NMN as defined herein above, R1 is ed from H and Cl-C6 alkyl, e.g. from H and Cl-C4 alkyl, or from H and Cl-C3 alkyl, e. g. from H, methyl and ethyl, or from H and methyl, e. g. R1 is H.

In some embodiments, R1 is ed from C1-C6 alkyl, e. g. from C1-C4 alkyl, or from C1- C3 alkyl; e.g. R1 is CH3. In some embodiments, R1 is selected from CH3 and CH3CH2.

In a compound of formula (I), ring A is phenyl or 5- or 6-membered heteroaryl.

When ring A is 5- or 6-membered heteroaryl, it may contain 1-4 atoms, such as l, 2 or 3 heteroatoms; or 1 or 2 heteroatoms, in particular 1 heteroatom, independently selected from N, O and S.

In some ments, ring A is 5- membered heteroaryl, containing 1-4 heteroatoms, such as l, 2 or 3 atoms; or 1 or 2 heteroatoms, in particular 1 heteroatom, independently selected from N, O and S.

In some embodiments, ring A is 6- membered heteroaryl, containing 1-4 heteroatoms, such as l, 2 or 3 heteroatoms; or 1 or 2 heteroatoms, in particular 1 heteroatom, independently selected from N, O and S.

W0 2015/110491 14 In some embodiments, ring A is . In some other embodiments, ring A is phenyl or 6- membered heteroaryl, e.g. ring A is 6-membered heteroaryl, such as pyridyl.

In still other embodiments, ring A is 5- or 6-membered aryl, e.g. thienyl or pyridyl. In some embodiments, ring A is 5-membered heteroaryl. In some embodiments, ring A is phenyl or 5-membered heteroaryl, e.g. ring A is phenyl or thienyl.

In those embodiments where ring A is phenyl, the compound of formula (I) may be represented by formula (Ia) (R4)m N/ \HRzlp W_H (Ia) wherein R1, each R2, R3, each R4, W, m and p are as defined herein.

In a nd of formula (I), the variable p, representing the number of substituents R2 on ring A, is an integer of from 0 to 3, e. g. from 0 to 2. In some embodiments, ring A is phenyl and p is 0, l or 2. In some ments, e. g. when ring A is a ered ring, e.g. ring A is phenyl, p is an integer of from 1 to 3, e.g. p is l or 2. In some embodiments, e.g. when ring A is a 6-membered ring, e.g. ring A is phenyl, p is 2 or 3, e.g. p is 2. In some other embodiments, e.g. when ring A is a 5-membered or 6-membered heteroaryl, e.g. A is thienyl or pyridyl, p is 0 or 1, e.g. p is 0.

When ring A is pyridyl, it e. g. may be 4-pyridyl.

In some embodiments, when ring A is 6-membered, e.g. in the embodiments when ring A is phenyl, R2 is not attached to an atom of ring A adjacent to the bond linking ring A to the pyrazolopyrimidine moiety ofthe compound of formula (I), i.e. R2 is not attached to a carbon atom in ortho on of ring A. Thus, when ring A is phenyl, any R2 is attached in meta or para position on ring A.

In some embodiments, when ring A is phenyl, the moiety W0 2015/110491 15 (R2), is selected from R2 R2 R2 ; egg. from R2 R2 R2 R2 R2 \/©/ and wherein each R2 is as defined herein.

In some embodiments, when ring A is phenyl and p is 0, l or 2, the moiety (R2), is selected from p $3 £5? b” wherein each R2 is as defined herein.

In some embodiments, when ring A is phenyl and p is l or 2, the moiety (R2), is selected from \(Q/ R2 wherein each R2 is as defined herein.

In some ular embodiments, when ring A is phenyl and p is 2, the moiety is W0 2015/110491 16 wherein each R2 is as defined herein.

In some embodiments, when ring A is phenyl and the integer p is 2 or 3, the moiety (R2) \/// is selected from R2 R2 and R2 wherein each R2 is as defined herein.

In some embodiments, ring A is selected from phenyl, said phenyl being substituted with 1-3 groups R2, e.g. l or 2 groups R2, in particular 2 groups R2; and pyridyl, e.g. 4-pyridyl, said pyridyl being substituted with 0, l or 2 groups R2, e.g. 0 or 1 group R2, in ular 0 group R2; and thienyl, said thienyl being tuted with 0 or 1 group R2, e. g. 0 group R2.

In some embodiments, ring A is selected from phenyl, said phenyl being tuted with 1-3 groups R2, e. g. l or 2 groups R2, in particular 2 groups R2; and thienyl, said l being substituted with 0 or 1 group R2, e. g. 0 group R2.

In some embodiments, ring A is selected from phenyl, said phenyl being substituted with 1-3 groups R2, e.g. l or 2 groups R2, in particular 2 groups R2; and pyridyl, e.g. 4-pyridyl, said pyridyl being substituted with 0, l or 2 groups R2, e. g. 0 or 1 group R2, in particular 0 group In some particular embodiments, the moiety flaw), may be represented by the formula W0 2015/110491 17 wherein Z is Z is N or CR2, R2 is as defined herein, and p is l, 2 or 3. In some embodiments, Z is N. In some embodiments, when Z is N, p is l (i.e. p-l is 0). In some other embodiments, Z is CR2. In some embodiments, when Z is CR2, p is 2 or 3, i.e. ring A is mono- or disubstituted.

In a compound of formula (I), each R2 is independently selected from Cl-C6 alkyl, RSO-, R6R7NC(O)-, R9C(O)N(R8)-, R100C(O)-, R“C(O)O-, and halogen; or two R2 attached to adjacent carbon atoms form er a methylenedioxy or ethylenedioxy biradical.

In some ments, each R2 is independently selected from C1-C6 alkyl, RSO-, R100C(O)-, and halogen or two R2 attached to adjacent carbon atoms form together a methylenedioxy or nedioxy cal.

In some embodiments, each R2 is independently selected from Cl-C6 alkyl, RSO-, and halogen; or two R2 attached to adjacent carbon atoms together form a methylenedioxy or ethylenedioxy biradical.

In some embodiments, each R2 is independently ed from Cl-C6 alkyl, RSO-, and halogen. In some embodiments, each R2 is independently selected from R50- and halogen.

In some other embodiments, each R2 is independently selected from R50- and Cl-C6 alkyl.

In still other embodiments, each R2 is R502 In some embodiments, each R2 is independently selected from R50- and n; or two R2 attached to adjacent carbon atoms together form a methylenedioxy or ethylenedioxy biradical.

In some embodiments, each R2 is independently selected from Cl-C6 alkyl and RSO-, or two R2 attached to nt carbon atoms together form a methylenedioxy or ethylenedioxy biradical.

In some embodiments, each R2 is independently selected from RSO-, or two R2 ed to adjacent carbon atoms together form a methylenedioxy or ethylenedioxy biradical.

W0 2015/110491 18 2015/051177 When R2 is C1-C6 alkyl, it more particularly may be Cl-C4 alkyl, or Cl-C3 alkyl, such as methyl and ethyl, in particular methyl.

When R2 is 1150—, R6R7NC(O)-, R9C(O)N(R8)-, or R100C(O)-, the moieties R5, R6, R7, R8 and R10 are independently selected from H and Cl-C6 alkyl, e.g. from H and Cl-C4 alkyl, e.g. H and Cl-C3 alkyl, such as H, methyl and ethyl, in ular H and methyl. In some ments, R5, R6, R7, R8 and R10 are independently selected from Cl-C6 alkyl, e. g. from Cl-C4 alkyl, or Cl-C3 alkyl, such as methyl and ethyl, in particular methyl.

When R2 is R9C(O)N(R8)- or R“C(O)O-, R9 and R11 are independently selected from Cl-6 alkyl; e.g. Cl-C4 alkyl, or Cl-C3 alkyl, such as methyl and ethyl, in particular .

When R2 is n, said halogen e. g. may be selected from F and Cl.

In some embodiments, ring A is phenyl, p is 2, and each R2 is independently selected from halogen and RSO-, or the two R2 are attached to adjacent carbon atoms and form together a methylenedioxy or ethylenedioxy biradical, e. g. ring A is phenyl, p is 2, and each R2 is RSO-, or the two R2 are attached to adjacent carbon atoms and form together a methylenedioxy or ethylenedioxy biradical.

In some embodiments, when two R2 are attached to adjacent carbon atoms and form together a methylenedioxy or ethylenedioxy biradical, said two R2 more particularly form a methylenedioxy biradical.

In some embodiments, when p is 2, the moiety (R2), is a moiety of formula O O’\ O o,R5 O o W0 2015/110491 19 n each R5 is as defined herein, e.g. each R5 is C1-C6 alkyl, or each R5 is Cl-C3 alkyl, e. g. each R5 is methyl.

In some embodiments, when p is 2, the moiety (R2), is a moiety of formula 0 O’\ QR, 0 wherein each R5 is as defined herein, e.g. each R5 is methyl.

In some embodiments, when p is 2, the moiety wherein each R5 is as defined herein, e. g. each R5 is methyl.

In a compound of formula (I), R3 is Cl-C6 alkyl, e.g. R3 is selected from Cl-C5 alkyl, or R3 is selected from Cl-C4 alkyl. In some embodiments, R3 is selected from Cl-C3 alkyl. In some embodiments, R3 is CH3. or H.

The moiety W isM N ‘2\/ w In some embodiments, .M Nwor H W is - - . In some ments, W is MN9V or w. In some other embodiments, Wis W0 2015/110491 20 N\2\/ w or H In some embodiments, W is M Nor W. In some other ments, W is NWor H or W In some embodiments, W isN . In some or i—i other embodiments, W is \g\/ w . In still other embodiments, W is 9V or w or H In still other embodiments, W isW In some particular embodiments, W isW.

In a compound of formula (I), ring B is 5- or 6-membered saturated or unsaturated carbocyclyl, 5- or 6-membered heteroaryl, or phenyl.

In some embodiments, ring B is 5- or ered saturated or unsaturated carbocyclyl. Any such carbocyclyl is non-aromatic and may be saturated (cycloalkyl) or egg. mono-unsaturated (cycloalkenyl), e. g. selected from cyclopentyl, cyclohexyl and cyclohexenyl. In some embodiments, when ring B is carbocyclyl, said carbocyclyl is saturated. In some embodiments, when ring B is carbocycylcyl, said carbocyclyl is ered. In some ments, when ring B is carbocycylcyl, said carbocyclyl is 6-membered. In some embodiments, ring B is cyclopentyl, cyclohexyl or cyclohexenyl. In some ments, ring B is cyclopentyl or cyclohexyl, e. g. ring B is cyclopentyl.

In some embodiments, ring B is 5- or 6-membered saturated or unsaturated carbocyclyl, or phenyl. In some embodiments, ring B is 6-membered saturated or unsaturated carbocyclyl, or phenyl, e. g. ring B is phenyl, cyclohexenyl or cyclohexyl.

In some embodiments, ring B is 5- or 6-membered heteroaryl. When ring B is 5- or 6- membered aryl, it e.g. may contain 1-4 heteroatoms, such as l, 2 or 3 heteroatoms; or I or 2 heteroatoms, or 1 heteroatom, independently ed from N, O and S.

In some embodiments, when ring B is 5- or ered heteroaryl, said heteroaryl is selected from pyridinyl and imidazolyl, e.g. pyridinyl, pyridinyl, nyl and lH-imidazol- W0 2015/110491 21 l-yl. In some other embodiments, when ring B is 5- or ered heteroaryl, said heteroaryl is selected from pyridinyl, olyl, dinyl, thienyl, thiazolyl, isoxazolyl, e. g. pyridinyl, pyridinyl, pyridinyl, lH-imidazol-l-yl, pyrimidinyl, thienyl, thiazolyl, and isoxazol—3-yl.

In some embodiments, ring B is 5-membered heteroaryl, containing one or more, e.g. 1-4, or 1-3, e. g. l or 2 heteroatoms, selected from N, O and S. When ring B is 5-membered heteroaryl, said heteroaryl e.g. may be selected from imidazolyl, l, lyl, isoxazolyl, e. g. lH-imidazol- l -yl, thienyl, lyl, and isoxazol—3-yl.

In some other particular ments, ring B is 6-membered heteroaryl, for example, containing one or more, 1-4, or 1-3, e.g. 1 or 2 heteroatoms, ed from N and 0.

When ring B is 6-membered heteroaryl, said heteroaryl e. g. may be selected from pyridinyl, i.e. pyridinyl, pyridinyl, pyridinyl, in particular it may be pyridinyl. In some other embodiments, when ring B is 6-membered heteroaryl, said heteroaryl is selected from pyridinyl and pyrimidinyl e. g. pyridinyl, pyridinyl, pyridinyl, and pyrimidinyl.

In some embodiments, when ring B is heteroaryl, said heteroaryl is not oxadiazolyl. In some embodiments, when ring B is heteroaryl at least one ring heteroatom is nitrogen, e.g. each ring heteroatom is nitrogen.

In some embodiments, when ring B is 5- or 6-membered heteroaryl, said heteroaryl contains 1 heteroatom. In some embodiments, when ring B is 5- or 6-membered heteroaryl, said heteroaryl contains 2 heteroatoms.

In some embodiments, ring B is 5- or 6-membered heteroaryl containing 1 heteroatom. In some other embodiments, ring B is 5- or 6-membered heteroaryl containing 2 heteroatoms.

In some embodiments, ring B is 5- or 6-membered aryl or phenyl, e. g. ring B is 6- membered heteroaryl or phenyl. In some other embodiments, ring B is 5-membered heteroaryl or phenyl.

In some embodiments, ring B is selected from W0 2015/110491 22 CM A /~_\ ~QM w New In some embodiments, ring B is phenyl.

When ring B is phenyl, the compound of the invention may be represented by formula (Ib) W». N/ Rzlp _ W—NMN wherein ring A, R1, each R2, R3, each R4, W, m and p are as defined herein.

The integer m represents the number of moieties R4 attached to ring B and is 0, l, or 2. In some embodiments, m is 0 or 1, e. g. m is 0. In other embodiments, m is 1 or 2. In some embodiments, m is 1. In some embodiments, m is 2.

For example, in some embodiments, ring B is phenyl or 5- or 6-membered aryl, and ring B is optionally tuted with 1-2 moieties R4.

In some embodiments, ring B is 5- or 6-membered heteroaryl, said heteroaryl optionally being substituted With l or 2 moieties R4.

In some embodiments, ring B is phenyl, m is l or 2, e. g. m is l, and one R4 is in para position on the phenyl ring.

When m is l or 2, each R4 is independently selected from Cl-C6 alkyl, R120, halogen, NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R198(O)2-, R2°S(O)2N(H)-, NHZS(O)2-, )-, (R23)-, and ‘o—.

In some embodiments, each R4 is independently selected from C1-C6 alkyl, R120, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)- and R18C(O)O-.

W0 2015/110491 23 In some embodiments, each R4 is independently selected from C1-C6 alkyl, R120, halogen, and R16C(O)N(R15)-. In some other embodiments, each R4 is independently selected from Cl- C6 alkyl, R120, and halogen. In still other embodiments, each R4 is independently selected from halogen and R120, e.g. each R4 is R120.

In some embodiments, two R4 attached to adjacent atoms of the ring B form, er with the atoms to which they are attached, a 5- or ered heterocyclic or carbocyclic ring, or a benzene ring. In some embodiments, two R4 ed to adjacent atoms of the ring B form, together with the atoms to which they are attached, a 5- or 6-membered cyclic ring or a benzene ring. In some ments, two R4 attached to adjacent atoms of the ring B form, together with the atoms to which they are attached a benzene ring. In some embodiments, two R4 attached to nt atoms of the ring B form, together with the atoms to which they are attached, a 5- or 6-membered heterocyclic ring.

When R4 is Cl-C6 alkyl, said alkyl e.g. may be selected from Cl-C4 alkyl, e.g. Cl-C3 alkyl, such as methyl and ethyl, in particular methyl.

When R4 is R120, R12 is selected from H and Cl-C6 alkyl. In some ments, R12 is selected from Cl-C6 alkyl, e. g. from Cl-C4 alkyl, in particular from Cl-C3 alkyl, such as methyl and ethyl, in particular methyl.

When R4 is halogen, said halogen e. g. may be selected from F, Cl and Br. In some embodiments, when R4 is halogen, said halogen is Cl or Br, in particular Cl. In some other embodiments, when R4 is halogen, said halogen is F or Cl, in particular said halogen is F.

When R4 is selected from R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R198(O)2-, RZOS(O)2N(H)-, R21C(O)-, and N(R22)(R23)-, each R13, R14, R15, R22 and R23 is independently selected from H and Cl-C6 alkyl, e.g. from H and Cl-C4 alkyl, or from H and Cl-C3 alkyl, e.g. from H and methyl; and each R16, R17, R18, R19, R20, and R21 is independently selected from Cl-6 alkyl, e. g. from Cl-C4 alkyl, in particular from Cl-C3 alkyl, such as methyl and ethyl, in particular methyl.

W0 2015/110491 24 When R4 is an alkyl moiety or comprises an alkyl , any such alkyl moiety may be substituted by one or more F.

When two R4 attached to adjacent atoms of the ring B form, together with the atoms to which they are attached, a 5- or 6-membered heterocyclic or carbocyclic ring, said ring e.g. may be ered. For example, two R4 attached to adjacent atoms of the ring B may together with the atoms to which they are attached, a l,3-dioxolane ring.

In some embodiments, the moiety (R4)m lobe is selected from In some embodiments, the moiety (R4)m is selected from moaoawmww W0 2015/110491 25 «Jammy mos/we iZ/H m CH CHgwmo: It should be realized that features of the various embodiments described herein may be freely combined within the scope of the present ion, unless mutually incompatible, or unless otherwise specified. For example, in some embodiments of the compound of formula (Ia), ring B is phenyl, as represented in formula (1b). In these embodiments, the compound may be represented by formula (Ic) (R4)m N‘/ / \/—l R2)p X \ N H (Io) _ W—NMN wherein R1, each R2, R3, each R4, W, m and p are as d herein.

W0 2015/110491 26 In some embodiments of the compound of formula (Ia), p is 2. In some embodiments of a compound of a (Ia), when p is 2, the compound is a compound of formula (Id) (R4)m N\/ / H (Id) W—NMN wherein R1, each R2, R3, each R4, W, m and ring B are as defined herein.

In some embodiments of a compound of formula (Id), ring B is phenyl or 5- or ered heteroaryl. In some other embodiments of a compound of formula (Id), ring B is phenyl.

In some embodiments of a nd of formula (Ia), egg. in some embodiments of a compound of formula (Id), each R2 is independently selected from Cl-C6 alkyl, R50- and halogen.

In some particular embodiments of a compound of formula (I), e. g. in a compound of formula (Ia), p is 2 and W is a methylene group. In some embodiments, when p is 2 and W is a methylene group, the compound of formula (Ia) is a compound as represented by formula (Ie) (R4)m R2 ‘fl N / / N (Ie) HNMN wherein ring B, R1, each R2, R3, each R4, and m are as defined herein.

In some particular embodiments of a nd of formula (Ie), ring B is phenyl, i.e. the compound may represented by formula (If) (If) W0 10491 27 wherein R- 1 each R2 3 R each R4, and m are as defined herein..

, , , In some embodiments of a compound of formula (Ib), i.e. in some embodiments of a compound of formula (Ic), in particular in some embodiments of a compound of formula (If), when m is l or 2, one moiety R4 is in para on on ring B. In some of these embodiments, mis 1.

In some embodiments of a compound of formula (If), m is l and R4 is in para position, i.e. the compound may be represented by formula (Ig) wherein R1, each R2, R3, and R4 are as d herein.

In some further embodiments a compound of formula (I) may be represented by formula (Ih) lib—Hm / N/N/ \ MP4 (Ih) n R1, each R2, R3, R4, m, ring B and Z are as defined herein and p is an integer of from lto3.

In formula (Ih), Z is N or CR2. In some embodiments, Z is N. In some embodiments, when Z is N, p is l (i.e. p-l is 0).

In some embodiments of a compound of formula (Ih), Z is CR2, in which case the compound may be represented by formula (Ij) W0 2015/110491 28 (Rom /, R2 N‘// \\ (R2>p-1 (I1) _\ N HNMN wherein R1, each R2, R3, each R4, m and ring B are as defined herein and p is an integer of from 1 to 3, e.g. p is l or 2, orp is 2.

In some embodiments of a compound of formula (I), e.g. in some embodiments of formula (Ih), or in some embodiments of formula (Ij), p is l or 2. In other embodiments of a compound of formula (I), e. g. in embodiments of formula (Ih), or in embodiments of formula (Ij), p is 1. In some particular embodiments, the compound may be represented by formula (1k) (R4>m / / \ / NN / (Ik) HNMN R3 wherein R1, R3, each R4, m, Z and ring B are as defined herein.

In some embodiments of a compound of a (I), e. g. in embodiments of formula (Ia), or formula (Id), or formula (Ie), or formula (Ih), or a (Ij), or a (Ik), ring B is 6- ed heteroaryl, said heteroaryl being substituted by a moiety R4 in para position or haVing a heteroatom, such as N, in para position, or ring B is phenyl, said phenyl being substituted by a moiety R4 in para position.

In some embodiments of a compound of formula (I), e.g. in embodiments of formula (Ia), or formula (Id), or formula (Ie), or a (Ih), or formula (Ij), or formula (Ik), ring B is 6- membered heteroaryl, said heteroaryl being substituted by a moiety R4 in para position or haVing a heteroatom, such as N, in para position.

In some embodiments of a nd of formula (I), e. g. in some embodiments of a compound of formula (Ih), or of formula (Ij) or of formula (Ik), ring B is phenyl, said phenyl being substituted by R4 in para position. In some embodiments, the compound may be represented by formula (Im) W0 2015/110491 29 wherein R1, R3, R4 and Z are as defined herein.

In some ments, in a compound of formula (Im), Z is CR2, and the compound may be represented by formula (In) HNMN wherein R1, R2, R3, and R4 are as defined herein.

It should be realized that, unless the ry is apparent fiom the context or specified, any reference herein to a compound of formula (I) also should be construed as a reference to a compound of any ofthe embodiments thereof, e.g. a compound according to any one of the formulas (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ij), (Ik), (Im) and (In).

As noted herein above, some of the compounds of formula (I) are novel. Thus, with the exceptions listed herein, novel compounds are provided according to a (Id) or according to formula (Ih).

In some embodiments, the novel compound is as represented by formula (Ie), provided that the compound is not chlorophenyl)methyl](3 ,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine, 3 -(3 ,4-dimethoxyphenyl)-N—[(4-methoxyphenyl)methyl] -2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine, 3 -(3 ethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo [l ,5-a]pyrimidinamine, N—(l ,3-benzodioxo l-5 -ylmethyl)-3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-pyrazo lo [ l ,5 - a]pyrimidinamine, W0 2015/110491 30 2015/051177 3 -(3 ,4-dimethoxyphenyl)-N—[(4-fluorophenyl)methyl] -2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[ l ,5-a]pyrimidin amine, or N—benzyl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[l,5-a]pyrimidinamine.

In some embodiments, the novel nd is as represented by formula (If), provided that the compound is not N—[(4-chlorophenyl)methyl](3 ,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[ l ,5- midinamine, 3 -(3 ,4-dimethoxyphenyl)-N—[(4-methoxyphenyl)methyl] -2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine, 3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo [l ,5-a]pyrimidinamine, N—(l ,3-benzodioxo l-5 -ylmethyl)-3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-pyrazo lo [ l ,5 - a]pyrimidinamine, 3 -(3 ,4-dimethoxyphenyl)-N—[(4-fluorophenyl)methyl] -2,5-dimethyl-pyrazolo[ l ,5- midinamine, or N—benzyl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[l,5-a]pyrimidinamine.

In some embodiments, the novel compound is as represented by formula (Ig), provided that the compound is not N—[(4-chlorophenyl)methyl] -3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine, 3 -(3 ,4-dimethoxyphenyl)-N—[(4-methoxyphenyl)methyl] imethyl-pyrazolo[ l ,5- a]pyrimidinamine, 3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo [l ,5-a]pyrimidinamine, 3 -(3 ,4-dimethoxyphenyl)-N—[(4-fluorophenyl)methyl] -2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine.

In some embodiments, the novel compound is as represented by formula (Ik), provided that the compound is not N—benzyl(4-fluorophenyl)-2,5-dimethyl-pyrazolo[ l ,5-a]pyrimidinamine, N—benzyl(4-fluorophenyl)methyl-pyrazo lo [ l ,5-a]pyrimidinamine, W0 2015/110491 31 N—benzyl(4-chlorophenyl)methyl-pyrazolo[1,5-a]pyrimidinamine, 2,5-dimethyl(p-tolyl)-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 2,5-dimethyl(p-tolyl)-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, uorophenyl)-2,5-dimethyl-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(4-fluorophenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, hlorophenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(4-chlorophenyl)-2,5-dimethyl-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(4-methoxyphenyl)-2,5-dimethyl-N-(3-pyridylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3 thoxyphenyl)-2,5-dimethyl-N-(4-pyridylmethyl)pyrazolo[ 1 ,5-a]pyrimidinamine, N—(cyclohexylmethyl)-2,5-dimethyl(p-tolyl)pyrazolo[1,5-a]pyrimidinamine, N—benzyl-2,5-dimethyl—3-(p-tolyl)pyrazolo[l,5-a]pyrimidinamine, 3-(4-methoxyphenyl)-2,5-dimethyl-N-(pyridinylmethyl)pyrazolo[1,5-a]pyrimidinamine, 3-(4-methoxyphenyl)-2,5-dimethyl-N-(pyridinylmethyl)pyrazolo[1,5-a]pyrimidinamine.

In some embodiments, the novel compound is as represented by formula (Im).

In some embodiments, the novel compound is as ented by formula (In).

Scheme 1 below illustrates suitable ways of synthesizing compounds of formula (I). For example, compounds of formula (I) may be formed from compounds of formula (III) by treatment with POC13 under reflux ions to give compounds of a (II), followed by reaction of amines using methods well-known to the person skilled in the art. Examples illustrating the synthetic methods are described in Griffith et al ( Bioorg. Med. Chem. Lett. 2011, 21, 645); Hwang et al (Bioorg. Med. Chem. Lett. 2012, 22, 7297-7301); Gilligan et al, (J. Med. Chem. 2009, 52, 3073-3083); Chen et al (Bioorg. Med. Chem. Lett. 2004, 14, 673); Tellew et al (Bioorg. Med. Chem. Lett. 2010, 20, 7259-7264); and Yu et al (Med. Chem. Lett. 2013, 4,230-234).

Compounds of formula (I) can also be formed form compounds of formula (IV) Via palladium-catalyzed synthetic methods such as Suzuki, Stille or Negishi reactions, depending on the halogen, as for example described in Gudmundsson et al (Bioorg. Med. Chem. Lett. 2009, 19, 5689-5692); Mayo et al (Adv. Synth. Catal. 2003, 345, 620-624); and US2006/0135526. Compounds of formula (I) may also be formed from compounds of W0 2015/110491 32 formula (V) by N—alkylations as described by Saito et al (Bioorg. Med. Chem. 2011, 19, 445.).

(R2), <R)p2 R1 R1 N// N‘// (R4)m N\// R2)p N N N ' a H o:(_/<N —> CIMN W—N R3 R3 R3 (III) (II) (R2) R1 R1 P (R4)m Hal (R4)m N / N‘/ / a M N / a w—wNH R3 R3 (IV) (V) Scheme 1 As illustrated below in scheme 2, compounds of formula (IV) can be formed from commercially available starting material (compounds of formula XIII and XIV) followed alkylation of the amine of formula (VI) by a method as described in Majo et al 2003 and references therein. Compounds of formula (IV) can also be formed from nds of formula (X) by treatment with POC13 to give compounds of formula (IX) by a method as described previously, followed by amination, as described in USZOO6/Ol35526 or Novinson et al (J. Med. Chem. 1977, 20(2), 296-299), to give compounds of formula (VIII).

Compounds of a (VIII) may then be nated using NIS or NBr to give nds of formula (IV) using methods as described in Labroli et al (Bioorg. Med. Chem. Lett. 2011, 21, 471-474), U820050187224 or USZOO6135526.

W0 2015/110491 33 NH2 R3 R4 R3 (XIV) (XIII) (VI) (IV) R1 R1 R1 NI? / Na (R4)m .g’N om _. CIMN _. a W—NMN R3 R3 R3 (x) (IX) (VIII) Scheme 2 As illustrated below in scheme 3, nds of formula (IV) can also be formed starting from compounds of formula (X), by treatment with a halogenating agent (e.g. SOClz, POClg, PC13, PBr3 etc) as described previously, to give compounds of formula (IX), which may then be treated with NBS or NIS to give compounds of formula (VII). Methods useful for synthesizing compounds of a (VII) from compounds of formula (X) are also described in 103052, WO2012033753 and Gudmundsson et al g. Med. Chem. Lett. 2009, 19, 5689-5692). Compounds of formula (VII) can then be reacted with amines to give compounds of formula (IV), by methods as bed by Gudmundsson et al (Bioorg. Med.

Chem. Lett. 2009, 19, 5689-5692) or Bel Abed (Tetrahedron Lett. 2013, 54(21) 2612-2614) R1 R1 R1 R1 N /I? N /I? N /I? (R4)m Hal N /(i o:(_/<N —> CIMN —> CIJ\\_/<N —> h R3 R3 R3 R3 (X) (IX) (VII) (IV) Scheme 3 As illustrated below in scheme 4, compounds of formula (III) and formula (X) can be formed from commercially available starting al (compounds of formula XV), by reaction with compounds of formula (X1) or (XII) under conditions described in, for example, Griffith et al W0 2015/110491 34 (Bioorg. Med. Chem. Lett. 2011, 21, 2641-2645); Hwang et al (Bioorg. Med. Chem. Lett. 2012, 22, 7297-7301); Chen et al (Bioorg. Med. Chem. Lett. 2004, 14, 3669-3673); Yu et al (Med. Chem. Lett. 2013, 4,230-234) or US2006/0135526.

(R2), (R2)p R1 N/ o o N/ R3J\/lk0’Alk / + glN / —’ o /N NH2 R3 (XV) (XII) (III) (XV) (XI) (X) Scheme 4 As illustrated below in scheme 5, compounds of formula (XI), a (X11) and formula (XIII) can be formed from commercially available ng material (compounds of formula XVI), by reaction with hydrazine under ions described in several of the above- ned publications (Labroli, Chen, Hwang, Griffith, Yu, Bel Abed etc). o R1 2 HN (XVI) H), (XII, Z=Ph-(R2)p) (XIII, z=HaI) Scheme 5 The term pharmaceutically acceptable salt of a compound refers to a salt that is pharmaceutically acceptable, as defined herein, and that possesses the desired pharmacological activity ofthe parent compound. Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids, e. g. hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid; or formed with organic acids, e.g. acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, W0 2015/110491 35 fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphtoic acid, oxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, lic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, etc.

In the preparation of acid addition salts, preferably such acid are used which form suitably therapeutically acceptable salts. Examples of such acids are hydrohalogen acids, sulfuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic or ic acids, such as formic acid, acetic acid, propionic acid, succinic acid, ic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid, halogenbenzenesulfonic acid, toluenesulfonic acid or naphthalenesulfonic acid.

Whenever a chiral carbon is present in a chemical structure, it is intended that all stereoisomers associated with that chiral carbon are encompassed by the structure, unless otherwise specified. Using the Cahn-Ingold-Prelog RS notational system, any tric carbon atom may be present in the (R)- or (S)-conf1guration, and the compound may be present as a mixture of its stereoisomers, e.g. a c mixture, or one stereoisomer only.

The present invention includes pharmaceutical compositions comprising at least one compound of formula (I), or an individual isomer, racemic or cemic mixture of isomers or a pharmaceutically able salt thereof, together with at least one pharmaceutically acceptable ent, e.g. a carrier, and optionally other therapeutic and/or prophylactic ingredients.

A pharmaceutical composition according to the invention may be for topical (local) or systemic administration, e.g. for enteral administration, such as rectal or oral administration, or for parenteral administration to a mammal (especially a , and comprises a eutically effective amount of a compound according to the invention or a pharmaceutically acceptable salt f, as active ingredient, in association with a pharmaceutically acceptable excipient, e. g. a pharmaceutically acceptable carrier. The therapeutically effective amount of the active ingredient is as defined herein above and W0 2015/110491 36 depends e.g. on the species of mammal, the body weight, the age, the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.

For enteral, e.g. oral, administration, the compounds of the invention may be formulated in a wide y of dosage forms. The pharmaceutical compositions and dosage forms may comprise a compound or compounds of the t invention or ceutically acceptable salt(s) thereof as the active component. The pharmaceutically acceptable carriers may be either solid or liquid. Solid form preparations include powders, tablets, pills, lozenges, es, s, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending , binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers e but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatine, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The ation of the active compound may comprise an encapsulating al as carrier, providing a e in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it.

Other forms suitable for oral administration include liquid form ations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents, for example, such as lecithin, an monooleate, or acacia.

Aqueous solutions can be prepared by ving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or tic gums, resins, cellulose, sodium carboxymethylcellulose, and other well-known suspending agents. Solid form preparations e solutions, suspensions, and emulsions, and may contain, in on to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.

W0 2015/110491 37 Exemplary itions for rectal administration include suppositories which can contain, for example, a suitable non-irritating excipient, such as cocoa , synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

The compounds of the invention also may be administered parenterally, e.g. by inhalation, injection or infilsion, e.g. by intravenous, intraarterial, intraosseous, intramuscular, intracerebral, intracerebroventricular, intrasynovial, intrastemal, intrathecal, intralesional, intracranial, utaneous and subcutaneous injection or infusion.

Thus, for parenteral administration, the pharmaceutical compositions of the invention may be in the form of a sterile injectable or infusible preparation, for e, as a sterile aqueous or oleaginous suspension. This sion may be formulated according to techniques known in the art using suitable sing or wetting agents (e.g., Tween 80), and suspending agents.

The e injectable or ble preparation may also be a sterile injectable or infilsible solution or suspension in a non-toxic parenterally acceptable diluent or solvent. For example, the ceutical composition may be a solution in l,3-butanediol. Other examples of acceptable vehicles and solvents that may be employed in the compositions of the present invention include, but are not limited to, mannitol, water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or ding medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of inj ectables, as are natural ceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.

These oil ons or suspensions may also contain a hain alcohol t or dispersant. ons for parenteral use also may contain suitable stabilizing agents, and if necessary, buffer substances. Suitable stabilizing agents include antioxidizing agents, such as sodium bisulfate, sodium sulfite or ascorbic acid, either alone or combined, citric acid and its salts and sodium EDTA. Parenteral solutions may also contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and cholorobutanol.

W0 2015/110491 33 For inhalation or nasal administration, suitable pharmaceutical ations are as particles, aerosols, powders, mists or droplets, e.g. with an average size of about 10 um in diameter or less. For example, itions for inhalation may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption ers to enhance bioavailability, fluorocarbons, and/or other solubilising or sing agents known in the art.

The pharmaceutical compositions of the invention also may be administered topically, to the skin or to a mucous membrane. For topical application, the pharmaceutical composition may be e.g. a lotion, a gel, a paste, a tincture, a transdermal patch, a gel for transmucosal delivery.

The composition may be formulated as a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for l administration of the compounds of this invention e, but are not limited to, mineral oil, liquid petroleum, white eum, ene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.

Alternatively, the pharmaceutical composition may be formulated as a suitable lotion or cream containing the active compound ded or dissolved in a r. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetaryl alcohol, 2-octyldodecanol, benzyl alcohol and water.

The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation.

Suitable pharmaceutical excipients, e.g. carriers, and methods of preparing pharmaceutical dosage forms are described in Remington’s Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in art of drug formulation.

The ceutical compositions may comprise from approximately 1 % to approximately 95%, preferably from approximately 20% to approximately 90% of a compound of formula (I), together with at least one pharmaceutically able excipient.

In general, the compounds of the invention will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. le daily dosages typically ranges from 1 to 1000 mg, e.g. l-500 mg daily, or l-50 mg W0 2015/110491 39 daily, depending upon us factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound used, the route and form of administration, and the indication towards which the administration is directed, etc. One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given e. Compounds of the invention may be administered as pharmaceutical formulations including those suitable for enteral or eral administration. The preferred manner of stration is generally oral using a convenient daily dosage regimen which can be ed according to the degree of affliction.

The compound of the present invention is contemplated as useful for the treatment of diseases caused by RNA viral infection in a mammal, e.g. non-enveloped single-stranded (+) RNA viral infection, in particular diseases caused by picomaviruses, which is either a human or animal, but preferably a human. The virus e.g. may be a Parechovirus (e. g. Ljungan or Parecho), a Cardiovirus (e. g. EMCV or r’s virus), Enterovirus (e. g. EV, Coxsackie, Polio, Rhino) or a virus. For veterinary use, the picomavirus may be e. g. an virus or a Teschovirus.

Diseases that are considered to be linked to, caused by, or otherwise associated with virus infection, e. g. by picomaviruses, are e. g. neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease, Huntington’s disease, poliomyelitis, encephalitis, meningitis, sepsis, cancer, paralysis, myocarditis, diabetes, common cold, hand-foot-and-mouth e, herpangina, pleurodynia, diarrhea, mucocutaneous lesions, respiratory illness, conjunctivitis, myositis, and chronic fatigue syndrome.

The present invention consequently also es a nd of formula (I) for use in the treatment of any of the above mentioned conditions, as well as the use of a compound of formula (I) in the manufacturing of a ment for the treatment of any of the above mentioned conditions.

The invention also includes a method of treatment of any of the above mentioned conditions, by administering to an animal or human in need thereof, a compound of formula (I).

W0 2015/110491 40 The invention is further illustrated by some non-limiting examples.

EXAMPLES In Table 1, the chemical name of some ifying nds for use of the invention (Ex. 1 to 71) and of some exemplifying novel compounds of the invention (Ex. 72 to 112) are given.

Table 1 Ex Chemical name N—[(4-chlorophenyl)methyl] -3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine 3 -(3 ,4-dimethoxyphenyl)-N—[(4-methoxyphenyl)methyl] -2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine 3 3 -(4-fluorophenyl)-2,5-dimethyl-N-( l -phenylethyl)pyrazo lo [ l yrimidinamine 4 N—benzylisopropylphenyl-pyrazolo[l,5-a]pyrimidinamine N—[2-(4-chlorophenyl)ethyl](3 ,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine 3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo [l ,5 -a]pyrimidin amine 3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-N-(3-phenylpropyl)pyrazo lo [ l ,5 -a]pyrimidin- 7-amine N—(l ,3-benzodioxo l-5 -ylmethyl)-3 -(3 ethoxyphenyl)-2,5-dimethyl-pyrazo lo [ l ,5 - a]pyrimidinamine 3 -(3 ,4-dimethoxyphenyl)-N—[(4-fluorophenyl)methyl] -2,5-dimethyl-pyrazolo[ l ,5- a]pyrimidinamine 3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-phenylpropyl)pyrazo lo [ l ,5 -a]pyrimidin- 7-amine N—(2-cyclohexen- l -ylethyl)-3 -(3 ,4-dimethoxyphenyl)-2,5 -dimethyl-pyrazolo[ l ,5- a]pyrimidinamine 3 -(3 ,4-dimethoxyphenyl)-N—[2-(2,4-dimethoxyphenyl)ethyl] -2,5-dimethyl- pyrazo lo [ l ,5 -a]pyrimidinamine l3 yl(4-fluorophenyl)-2,5-dimethyl-pyrazolo[ l ,5-a]pyrimidinamine W0 2015/110491 41 EX Chemical name 14 3-(4-flu0r0pheny1)-2,5-dimethyl-N—phenethyl-pyrazo10[1,5-a]pyrimidinamine N—[2-(3,4-dimethoxypheny1) ethy1](4-fluor0pheny1)-2,5-dimethy1—pyraz010[ 1 ,5- a]pyrimidinamine yc10hexen— 1 -y1ethy1)(4-fluoropheny1)-2,5-dimethy1—pyrazo 10[1,5- a]pyrimidinamine 17 uoropheny1)-2,5-dimethy1—N—(1-pheny1ethy1)pyraz010[1,5-a]pyrimidinamine 18 N—benzy1(4-fluoropheny1)methy1—pyraz010[1,5-a]pyrimidin—7-amine N—[2-(3,4-dimethoxypheny1)ethy1](4-fluoropheny1)methy1—pyraz0 10[1,5- a]pyrimidinamine -tert-buty1—N—(2-cyclohexen— 1 y1)(4-flu0r0pheny1)methy1—pyraz010[ 1 ,5- a]pyrimidinamine 21 N—benzyl-S-methy1pheny1-pyraz010[1,5-a]pyrimidin—7-amine N—[2-(3,4-dimethoxypheny1)ethy1]methy1—3-pheny1-pyraz010[1,5-a]pyrimidin amine 23 5-tert-buty1—N—(3-imidaz01—1-y1propy1)pheny1-pyrazo10[1,5-a]pyrimidin—7-amine N—(3-imidaz01—1-y1propy1)methy1—3-pheny1pr0py1—pyraz010[1,5-a]pyrimidin amine N—benzy1(4-ch10ropheny1)methy1—pyraz010[1,5-a]pyrimidinamine 26 3-(4-ch10r0pheny1)methy1—N—phenethy1—pyrazo10[1,5-a]pyrimidin—7-amine 3-(4-ch10r0pheny1)-N—[2-(3,4-dimethoxypheny1)ethy1]methy1—pyraz0 10[1,5- a]pyrimidinamine 3-(4-ch10r0pheny1)-N—(3-imidaz01—1-y1pr0py1)methy1—pyraz010[1,5-a]pyrimidin amine N—[2-(3,4-dimeth0xy pheny1)ethy1]methy1—3-(p-t01y1)pyrazo10[1,5-a]pyrimidin amine N—[2-(3,4-dimethoxypheny1) ethyl]ethy1methy1—3-pheny1-pyraz010[1,5- a]pyrimidinamine 2-ethy1-N—(3-imidaz01—1-y1propy1)methy1—3-pheny1-pyraz010[1,5-a]pyrimidin amine 3-(4-ch10ropheny1)-2,5-dimethy1—N—[2-(p-t01y1)ethy1]pyraz010[1,5-a]pyrimidin amine 33 2,5-dimethy1—3-(p-t01y1)-N—(2-pyridy1methy1)pyraz010[1,5-a]pyrimidin—7-amine W0 2015/110491 42 EX Chemical name 34 2,5-dimethy1—3-(p-t01y1)-N—(3-pyridy1methy1)pyrazolo[ 1 ,5-a]pyrimidin—7-amine 3-(3,4-dimethoxyphenyl)-2,5-dimethy1—N—(2-pyridy1methy1)pyrazolo[1,5-a]pyrimidin- 7-amine 3-(4-flu0r0phenyl)-2,5-dimethy1—N—(3-pyridy1methyl)pyrazolo[1,5-a]pyrimidin amine u0r0phenyl)-2,5-dimethy1—N—(2-pyridy1methyl)pyrazolo[1,5-a]pyrimidin amine 38 N—cyclopentyl(4-fluor0pheny1)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin—7-amine 39 2,5-dimethy1—3-pheny1—N—(3-pyridy1methy1)pyrazolo[1,5-a]pyrimidin—7-amine 40 N—benzyl(3 ,4-dimethoxyphenyl)-2,5-dimethy1—pyrazo10[1,5-a]pyrimidin—7-amine N—cyclopentyl(3,4-dimeth0xyphenyl)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin amine 3-(4-ch10r0phenyl)-2,5-dimethy1—N—(2-pyridy1methyl)pyrazolo[1,5-a]pyrimidin amine N—cyclohexyl(3,4-dimeth0xyphenyl)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin amine 3-(4-ch10rophenyl)-N-(3-imidazol—1-y1pr0py1)-2,5-dimethy1—pyraz010[1,5- midinamine 3-(4-ch10r0pheny1)-2,5-dimethy1—N—(3-pyridy1methyl)pyrazolo[ 1 ,5-a]pyrimidin amine N—(4-brom0pheny1)(3,4-dimeth0xyphenyl)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin- 7-amine N—(4-ch10r0phenyl)(3,4-dimethoxypheny1)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin- 7-amine 48 3-(3,4-dimeth0xyphenyl)-2,5-dimethy1—N—(p-t01y1)pyraz0lo[1,5-a]pyrimidin—7-amine 3-(3,4-dimeth0xypheny1)-N—(4-meth0xyphenyl)-2,5-dimethy1—pyraz0 10[1,5- a]pyrimidinamine 50 3 -(3 eth0xyphenyl)-2,5-dimethy1—N—(m—to1y1)pyraz0 10 [ 1 ,5-a]pyrimidinamine N—(3-ch10rophenyl)(3,4-dimethoxypheny1)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin- 7-amine 3-(3,4-dimeth0xypheny1)-N—(3,4-dimethy1phenyl)-2,5-dimethy1—pyraz010[ 1 ,5- a]pyrimidinamine W0 2015/110491 43 EX Chemical name 3-(3 ,4-dimethoxyphenyl)-N-(4-fluor0pheny1)-2,5-dimethy1—pyrazolo[1,5-a]pyrimidin- 7-amine -dimethoxypheny1)-N—(4-eth0xypheny1)-2,5-dimethy1—pyrazolo[1,5-a]pyrimidin- 7-amine N—(3-ch10r0methy1—pheny1)(3,4-dimethoxyphenyl)-2,5-dimethy1—pyrazo 10[1,5- a]pyrimidinamine 3-(3,4-dimeth0xypheny1)-N—(3,5-dimethy1phenyl)-2,5-dimethy1—pyraz010[ 1 ,5- a]pyrimidinamine 57 3-(3,4-dimethoxypheny1)-2,5-dimethy1—N—pheny1—pyrazolo[1,5-a]pyrimidin—7-amine N—[4-[[3-(3,4-dimethoxy pheny1)-2,5-dimethy1—pyrazolo[1,5-a]pyrimidin yl]amino]pheny1]acetamide N—(3,4-dich10rophenyl)(3,4-dimethoxyphenyl)-2,5-dimethy1—pyrazolo[1,5- a]pyrimidinamine 3-(3,4-dimeth0xypheny1)-N—(4-isopropylpheny1)-2,5-dimethy1—pyrazolo[1,5- a]pyrimidinamine 3-(3,4-dimethoxyphenyl)-N—(3-meth0xypheny1)-2,5-dimethy1—pyraz0 10[1,5- a]pyrimidinamine 3-(3 ,4-dimethoxyphenyl)-N—(4-ethylphenyl)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin- 7-amine uty1phenyl)(3,4-dimethoxyphenyl)-2,5-dimethy1—pyraz010[1,5-a]pyrimidin- 7-amine N—(3 ,5 oropheny1)-3 -(3 ,4-dimethoxyphenyl)-2,5 -dimethy1—pyrazolo[ 1 ,5 - a]pyrimidinamine 3-(4-methoxypheny1)-2,5-dimethy1—N—(3-pyridy1methyl)pyraz010[ 1 ,5-a]pyrimidin amine 3 -(4-methoxyphenyl)-2,5-dimethyl-N—(4-pyridy1methyl)pyraz010[ 1 ,5-a]pyrimidin amine N—(3-imidaz01—1-y1pr0pyl)(4-meth0xyphenyl)-2,5-dimethy1—pyraz010[1,5- a]pyrimidinamine 3-(4-methoxyphenyl)-2,5-dimethy1—N—[2—(2-pyridy1)ethy1]pyrazo10[1,5-a]pyrimidin amine 69 2,5-dimethy1—N—(3-pyridy1methy1)(2-thienyl)pyraz010[1,5-a]pyrimidinamine W0 2015/110491 44 EX Chemical name 70 2,5-dimethyl-N—(4-pyridylmethy1)(2-thienyl)pyraz010[1,5-a]pyrimidinamine N—(3-imidaz01—1-y1pr0py1)-2,5-dimethy1—3-(2-thieny1)pyrazolo[1,5-a]pyrimidin amine 3-(3,4-dimethoxyphenyl)-2,5-dimethy1—N—[[4- oromethy1)pheny1]methyl]pyrazo10 [ 1 ,5-a]pyrimidin—7-amine 3-(3,4-dimethoxyphenyl)-2,5-dimethy1—N—[4-(trifluoromethyl)phenyl]pyrazo10[ 1 ,5- a]pyrimidinamine -dimeth0xyphenyl)-2,5-dimethy1—N—(4-pyridyl)pyraz010[1,5-a]pyrimidin amine 3-(3,4-dimethoxyphenyl)-2,5-dimethy1—N—(4-pyridylmethy1)pyrazolo[1,5-a]pyrimidin- 7-amine 3-(3,4-dimethoxyphenyl)-2,5-dimethy1—N—[[4- (trifluoromethoxy)pheny1]methy1]pyraz010[1 ,5-a]pyrimidinamine N—[4-[[[3-(3,4-dimethoxypheny1)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]acetamide 3 -(3 ,4-dimethoxypheny1)-N—[(4-dimethylaminophenyl)methy1] -2 5 -dimethy1— pyraz010[ 1 ,5 -a]pyrimidin—7-amine 3-(3 ,4-dimeth0xyphenyl)-N—[(6-meth0xypyridy1)methy1]—2,5-dimethy1— pyraz010[ 1 ,5 -a]pyrimidin—7-amine N—[4-[[[3-(3,4-dimethoxypheny1)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]methanesulfonamide 4-[[[3-(3,4-dimethoxypheny1)-2,5-dimethy1—pyrazolo[ 1 ,5-a]pyrimidin—7- yl]amino]methy1]phenol 3-(3,4-dimethoxyphenyl)-2,5-dimethy1—N—[(3- methylsulfonylphenyl)methyl]pyrazo10 [ 1 ,5-a]pyrimidin—7-amine 3 -(3 ,4-dimeth0xyphenyl)-2,5-dimethy1—N—[(1-0Xidopyridinium—4- y1)methyl]pyraz0 10 [ 1 ,5 imidin—7-amine 3-(3,4-dimethoxyphenyl)-2,5-dimethy1—N—[(4- methylsulfonylphenyl)methyl]pyrazo10 [ 1 yrimidin—7-amine 3 -(3 ,4-dimeth0xyphenyl)-2,5-dimethy1—N— [2-(2-pyridyl)ethyl]pyrazo10[ 1 ,5- a]pyrimidinamine W0 2015/110491 45 EX Chemical name N-[(4-tert-butylpheny1)methyl](3,4-dimethoxyphenyl)-2,5-dirnethy1—pyrazolo[1,5- a]pyrirnidinarnine 3 -(3 ,4-dimethoxypheny1)-2 5 -dirnethy1—N— [(2-rnethylpyrirnidin y1)methyl]pyrazo 10 [ 1 ,5 irnidin—7-arnine 3-(3,4-dimethoxyphenyl)-2,5-dirnethy1—N—[2-(2-thieny1)ethyl]pyrazo10[1,5- a]pyrirnidinarnine 3 -(3 ,4-dimethoxyphenyl)-2,5 -dirnethy1—N— [2-(4-pyridyl)ethyl]pyrazo10[ 1 ,5- a]pyrirnidinarnine 3 -(3 ,4-dimethoxyphenyl)-2,5-dimethyl-N—pyrazin—2-y1-pyraz0 10 [ 1 ,5 -a]pyrirnidin amme 3 -(3 ,4-dirnethoxyphenyl)-N-indan—2-yl—2,5 -dirnethy1—pyrazolo[ 1 ,5 -a]pyrirnidin amme 3 -(3 ,4-dimethoxyphenyl)-2,5 -dirnethy1—N— [(6-rnethyl-3 -pyridy1)rnethyl]pyrazolo[ 1 ,5- a]pyrirnidinarnine N—[3 -(3 ,4-dimethoxyphenyl)-2,5 -dirnethy1—pyrazolo[ 1 ,5 -a]pyrirnidin—7-y1]—5 -rnethy1— thiazo 1arnine 1- [4- [[[3 -(3 ,4-dimethoxyphenyl)-2,5 -dirnethy1—pyrazolo[ 1 ,5 -a]pyrirnidin no]rnethy1]phenyl]ethanone N—[3 -(3 ,4-dimethoxyphenyl)-2,5 -dirnethy1—pyrazolo[1,5 irnidin—7-y1]isoxazo1-3 - amme 3 -(3 ,4-dimethoxyphenyl)-2,5-dimethy1—N—( 1 -naphthy1methyl)pyrazo 10 [ 1 ,5 - a]pyrirnidinarnine 4- [ [ [3-(3 ,4-dimethoxyphenyl)-2,5 -dirnethy1—pyrazolo[1,5 -a]pyrirnidin—7- yl]amino]rnethyl]benzenesulfonamide 3 -(3 ,4-dimethoxyphenyl)-2,5 thy1—N—[1-(4-pyridy1)ethyl]pyrazo10[ 1 ,5- a]pyrirnidinarnine 3 -(3 ,4-dimethoxyphenyl)-N-[(4-fluor0phenyl)methyl] -5 -rnethy1—pyrazo 10 [ 1 ,5 - rnidinarnine 3 -(3 ,4-dirnethoxyphenyl)-5 -rnethy1—N—(4-pyridylrnethyl)pyrazo10[ 1 ,5-a]pyrirnidin 1 00 amme 3 -(3 ,4-dirnethoxyphenyl)-5 -rnethy1—N— [(3 -methylsulfonylphenyl)rnethyl]pyrazo10[ 1 ,5- a]pyrirnidinarnine W0 10491 46 Ex Chemical name 3 -(1 ,3-benzodioxo 1-5 -y1)-N- [(4-fluoropheny1)methy1] -2,5 -dimethy1—pyrazolo[ l ,5- midinamine 3 -(3 ,4-dichlorophenyl)-N—[(4-fluoropheny1)methy1]-2,5-dimethy1—pyrazolo[ l ,5- a]pyrimidinamine N—[(4-fluoropheny1)methy1] -2,5-dimethy1—3 -[4-(trifluoromethy1)pheny1]pyrazo lo [ l ,5 - 1 04 a]pyrimidinamine N—[(4-fluoropheny1)methy1] -2,5-dimethy1—3 -(3 ,4,5-trimethoxyphenyl)pyrazolo[ l ,5 - a]pyrimidinamine 3 -(3 ,4-difluoropheny1)-N—[(4-fluoropheny1)methy1]-2,5-dimethy1—pyrazolo[ l ,5- a]pyrimidinamine methyl 4- [7-[(4-fluoropheny1)methylamino] -2,5-dimethy1—pyrazolo[ l ,5 -a]pyrimidin- 1 ()7 3 -y1]benzoate 3 -(3 -fluoromethoxy-pheny1)-2,5-dimethy1—N—(p-toly1methyl)pyrazo lo [ l ,5- 1 08 a]pyrimidinamine 3 -(3 ,4-diethoxyphenyl)-N—[(4-fluoropheny1)methy1]-2,5-dimethy1—pyrazolo[ l ,5- midinamine -dimethy1(p-toly1methy1amino)pyrazolo [ l ,5 -a]pyrimidin-3 -y1]benzene- l ,2- 1 10 diol 3 -(3 ,4-dimethoxypheny1)-N—[(4-fluoropheny1)methy1]isopropy1—2-methy1— 1 1 1 pyrazo lo [ l ,5 -a]pyrimidin—7-amine N—[(4-fluoropheny1)methy1] -2,5-dimethy1—3-(4-pyridy1)pyrazolo[ l ,5 -a]pyrimidin 1 12 am1ne In Table 2, the structural formulas of the compounds of Examples 1-112 are given.

Table 2 EX. 1 EX. 2 EX. 3 \O \O F O\ O\ N/ N’ N’ CHMHN N EX 4 EX 5 E 6 N\ / /0 QHN \ N / // H N N\N\ N EX 7 EX 00 E 9 IO /O \ \ H NJVN H N N o JV/ F EX 1 0 EX 1 1 E 1 2 ’0 ’0 N\ / / / / N H N HN / N\N\ N/ 6 O EX 1 3 EX 1 4 E 1 5 I \ myHN4HN H N \ N/ HN / 6 EX 1 6 EX 1 7 E 1 00 F F N| / / / H NN/MN WHN NN\ N/ WO 10491 48 EX. 19 EX. 20 EX. 21 Nfl/UF F NNW N /Nil/KD 5M HN \, N HN N @M EX. 22 EX. 23 EX. 24 : N / N / : NN/Z N / N /Z HN N HN N a?M / ”1\ m / NV \ EX. 25 EX. 26 EX. 27 CI CI N /NW / NW NQ/Q/CI/ C HNM HNM HNM EX. 28 EX. 29 EX. 30 0 o fl \ / EX. 31 EX. 32 EX. 33 / N / N / N.N / W NW N§/N WO 10491 49 EX. 34 EX. 35 EX. 36 \O F N ’ I N ’ ‘N / O ‘N / N_ HN N N/ \ N_ HN N / ‘ / N M Cw \ / EX. 37 EX. 38 EX. 39 F F N’NW Q N/ N/ ‘N / 'N / QMNHN \ N HNM\ N wN_ HN N / \ / / EX. 40 EX. 41 EX. 42 \o \0 CI 0/ 0/ W 0 WM WM EX. 43 EX. 44 EX. 45 \0 CI CI / / / Q 4N ’ HN N N_ HN N N M HNM / NJ—/M Q4 / NV EX. 46 EX. 47 EX. 48 \o \o \o WO 10491 50 EX. 52 EX. 67 EX. 70 EX. 71 EX. 72 / \ / \ / F3C N, N / N ‘N / S ‘N / S OVN HNJ\\_<N HN N ‘N' /N / \ J\\_< T\( o / NJ—/ / _ CH3 EX. 73 EX. 74 EX. 75 CH3 CH3 CH3 N, N, , N— D If” 0 N / p” o If“ 0 F30 / / / CH3 CH3 CH3 EX. 76 EX. 77 EX. 78 CH3 \o \o ,o ’ F30 @Nfimd CH3 CH3 Ox 0\ ‘ O ’ N :<CH3 O ”7/ \ O N// N N N N CH3 NMN / Q—NMN CH3 CH3 EX. 79 EX. 80 EX. 81 \O \O 0/ N/CH3 CH O\ CH3 3 \llo 0\ N 023 N’ N / /O@_\N\ ‘ / ‘ ‘ N / \ N / N N©—\ M HO N NJ\\_/<N N \ N EX. 82 EX. 83 EX. 84 \O 0/ \o CH3 0 CH3 \ p 0\ 0\ 0:8 / N ’ N / —/§4©—\0“ N / ‘N / / N N _ O-NC\>—\ N — NMN O / NMN CH3 3 EX. 85 EX. 86 EX. 87 O/ O/ O/ / / / _ CH3 CH 0 3 o O \ / N N/ / N// \l_N)_\ N/ / N N N \ N N N — EX. 88 EX. 89 EX. 90 \o \0 0/ CH / CH N— CH 3 O 3 3 S O\ 0\ \ / N/ , NW ‘ N/ N / ‘N / / N N <\_/< N N N/ N4<\—/<N CH3 3 EX. 91 EX. 92 EX. 93 CH3 0/ CH3 0 CH3 0/ “V/ %N‘N / \f/N ”7/ N — NMN S N NMN N N CH3 M CH3 CH3 EX. 94 EX. 95 EX. 96 CH3 0 CH3 (4 0 CH3 0/ CHI-I3 >fi NN / 0\N N/ \ / ‘ / N// o NJ\\—’<N N O N N N CH3 NMN M EX. 97 EX. 98 EX. 99 o’ \ 0/ CH3 0 / (1 O / O H2N—’\S_©_\\ N / ’ N N/ F N\N / // “Ix/(N N / S NMN CH NH N EX. 100 EX. 101 EX. 102 O/ 0/ CH3 \ o’ F O o=s=O N / / @N 9" O O / N / N \ / \N / WTYN OJ N N — NMN NMN CH3 53 2015/051177 EX. 103 EX. 104 EX. 105 CH3 CH3 CH3 \ Ffly” I)" F l)" F N/ N / N / CI Q“{KN CFs \QVN “1 / 0/ EN CI If“ 0 CH3 CH3 CH3 EX. 106 EX. 107 EX. 108 CH3 \0 F F N/ CH3 CH3 0 CH3 J\\_,< NJ\\_/<N CH3 CH3 EX. 109 EX. 110 EX.111 A OH 0’ O OH CH3 d O\/ N / N/ / / N/ N F4< N F ‘N / 4< >—\ >—\ J\\_/< NV/ N NW/ N EX. 112 / \ / N N / EXAMPLES 72-98 The compounds of Examples 72-98 were synthesized by following the General Procedure A described herein below.

General Procedure A O Step-2 HN 0V | NH2-NH2.HC| \ if 0 \ o // —> H2N N EtOH Step-3 O / | o W0 2015/110491 54 OH C' fN/N\ Step-'4 Step-_5 \ \ N \fN;N\ N F:NHNN POCIs R--NH2 4 5 Ex. 72-98 Step-1 To a solution of 1 (10.0 g, 56.4 mmol) in ethyl acetate (200 mL) was added sodium metal (2.6 g, 112.8 mmol) portion wise at 0-5 c’C under nitrogen atmosphere. The reaction mixture was stirred at room ature for 6h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was cooled to 0-5°C quenched with methanol (50 mL) and the solvent was evaporated under pressure. The ant solid was dissolved in water (100 mL) and washed with e (2 X 100 mL). The aqueous solution was acidified with acetic acid (pH: 4 to 5) and extracted with dichloromethane (3 X 100 mL). The combined organic layer was washed with water, brine, dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude material was purified by recrystallization using ethyl acetate and hexane to afford 2 (9.5 g, 76.8%) as a pale brown solid.

Step-2 To a solution of 2 (9.0 g, 41.05 mmol) in ethanol (90 mL) were added ine monohydrochloride (4.218 g, 61.57 mmol) and acetic acid (2.7 mL) at room temperature under nitrogen atmosphere. The reaction mixture was heated to 85 oC and stirred for 5-6 h.

The on was monitored by TLC. After completion of the reaction, the reaction mixture was cooled to room temperature. The reaction mixture was quenched with water (90 mL) and concentrated under reduced pressure. The resultant aqueous layer was washed with toluene (3 X 45 mL) and d with 10% aq. sodium bicarbonate solution (pH: 8-9). The aqueous layer was extracted with dichloromethane (4 X 50 mL). Combined organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to afford 3 (7.6 g, 79.36%) as an off-white solid. The product ed was used without further purification.

W0 2015/110491 55 Step-3 To a solution of 3 (8.0 g, 21.4 mmol) in acetic acid (80 mL) was added ethyl acetoacetate (9 mL, 42.8 mol) at room temperature and heated to 105 0C for 6 h. The progress of the reaction was red by TLC. After completion, the reaction mass was trated under high vacuum at 50 CC. The resultant solid was diluted with water and extracted with dichloromethane (3 X 10 mL). The combined organic extract was washed with 10% sodium bicarbonate solution, water and brine. The organic extract was dried over sodium sulphate, filtered and concentrated under vacuum at 50 oC. The residue obtained was treated with dichloromethane (25 mL). The solid was d and dried under vacuum to afford pure 4 (9.5 g, 92.54%) as a colorless solid.

Step-4 To a suspension of 4 (2.0 g, 6.68 mmol) in dry toluene (30 mL) were added oryl chloride (6.24 mL, 6.68 mmol) and N,N—diethyl aniline (2.14 mL,13.36 mmol) at room temperature under nitrogen atmosphere. The reaction mass was heated to 105 °C for 16 h.

After 16 h, the reaction mass was trated under high vacuum at 50-55 0C and co- evaporated with toluene under high vacuum at 50-55 0C. To the residue was added water (40 mL), followed by extraction with dichloromethane (3 X 40 mL), and the combined c layer was washed with water, brine and dried over sodium sulphate. The organic layer was concentrated under vacuum at 45-50 0C to get crude compound. The crude compound was purified by flash column chromatography using ethyl acetate and hexane as eluant to afford 5 (2.1 g, 98.9%) as a yellow solid.

Step-5 To a solution of 5 (1.0 eq.) in toluene or acetonitrile or DMF (10-20 V) were added the tive amines (1.3 eq.) and base [DIPEA (5 V)/ K2C03 / KOtBu / NaH (2.0 eq.)] sequentially. The reaction e was then heated to 90 CC and stirred well for 16 h. The progress of the reaction was red by TLC. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (20 V) and extracted with dichloromethane (3 X 10 V). The combined organic extract was washed with water, brine, dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude material was purified by flash column chromatography (silica gel, 50% EtOAc in hexane) to afford the desired compounds with >95% HPLC purity.

W0 2015/110491 56 EXAMPLES 99-101 The compounds of Examples 99-101 were synthesized by following the General Procedure B.

General Procedure B O HN—N N / N // \ / H2N \ o o o /\OJJ\ ,NH2 H2N HCI MON \0 Step-1 \o Step-2 \O Step_3 0\ O\ O\ 6 7 8 fir“ ”N ,N / \ cation + N\\ o N —> o/ / /O / 9 ) 10 (Minor) 0 CI HN’ fiN POCI3 R-NH2 ,N / /N ,N \ _. \ _. fl“ \ \ \ \ \ \ M N Step-4 Step-5 N / / O O O/ /O O / /O 9 11 EX.99-101 Step-1 To a suspension of 6 (5.0 g, 28.22 mmol) and sodium methoxide (3.81 g, 70.5 mmol) in diethyl ether (75 mL) was added a solution of ethyl formate (2.6 mL, 2.4 g, 32.32 mmol) in diethyl ether (25 mL) slowly at room temperature under nitrogen atmosphere. The suspension was stirred for another 16 h at room temperature. The solid formed was filtered and washed with l ether (25 mL). The solid was then dissolved in minimum amount of water and acidified with acetic acid. The solid formed was filtered, washed with water and dried under vacuum to give pure 7 (4.8 g, 83%) as a pale yellow solid.

W0 2015/110491 57 Step-2 To a solution of 7 (4.5 g, 21.95 mmol) in ethanol (90 mL) was added ine monohydrochloride (2.25 g, 32.92 mmol) and acetic acid (12 mL) at room temperature under nitrogen atmosphere. The reaction mixture was heated to 85 CC and stirred for 3-4 h. The reaction was monitored by TLC. After completion of the reaction, the on e was cooled to room temperature. The reaction mixture was quenched with water (45 mL), concentrated under d pressure. The resultant s layer was washed with toluene (3 X 45 mL) and basified with 10% aq. sodium onate on (pH: 8-9). The aqueous layer was extracted with dichloromethane (4 X 50 mL). Combined organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to afford 8 (3.5 g, 75%) as an off-white solid. The product obtained was used without fiarther purification.

Step-3 To a solution of 8 (4.0 g, 18.25 mmol) in acetic acid (40 mL) was added ethyl acetoacetate (2.55 mL, 18.253 mmol) at room temperature followed by heating to 105 CC for 6 h. The progress of the reaction was monitored by TLC. After completion, the reaction mass was concentrated under high vacuum at 50 oC. The resultant solid was d with water and extracted with dichloromethane (3 X 10 mL). The combined organic extract was washed with 10% sodium bicarbonate solution, water and brine. The organic extract was dried over sodium sulphate, filtered and concentrated under vacuum at 50 oC. The residue ed was triturated with dichloromethane (25 mL) to afford pure 9 (5 g, 96%) as an off-white solid.

Step-4 To a suspension of 9 (5.0 g, 17.525 mmol) in dry toluene (75 mL) were added phosphoryl chloride (16.38 mL, 175.2 mmol) and N,N—diethyl aniline (5.62 mL, 35.05 mmol) at room temperature under nitrogen atmosphere. The reaction mass was heated to 105 °C for 16 h.

After 16 h, the reaction mass was concentrated under high vacuum at 50-55 0C and co- evaporated with e under high vacuum at 50-55 0C. To the residue was added water (40 mL), extracted with dichloromethane (3 X 40 mL), the combined organic layer were washed with water, brine and dried over sodium sulphate. The organic layer was concentrated under vacuum at 45-50 0C to get crude compound. The crude compound was purified by flash column chromatography using ethyl acetate and hexane as eluent to afford 11 (4.5 g, 84.58%) as a yellow solid.

W0 2015/110491 53 Step-5 To a on of 11 (1.0 eq.) in toluene or acetonitrile or DMF (10-20 V) were added the respective amines (1.3 eq.) and base [DIPEA (5 V)/ K2C03 / KOtBu / NaH (2.0 eq.)] sequentially. The reaction mixture was then stirred at room temperature or at 90 CC for 16 h.

The ss of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature and trated under reduced pressure. The residue was diluted with water (20 V), extracted with dichloromethane (3 X 10 V). The combined organic extract was washed with water, brine, dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude material was purified by flash column chromatography a gel, EtOAc in Hexane as eluent) to afford the desired compounds with >95% HPLC purity.

EXAMPLES 102-108 The compounds of Examples 102-108 were synthesized by following the General Procedure E described herein below.

General ure E o H AcOEt ,NH2 ,N R/\\\N _. —> \ —» R \ Step-1 \ N Step-2 R Step-3 12 a-g 13 a-g 14 a-g 0 CI i 3 N’ POCI / N’N H N I \\ 3 \ 2 / N’N\ Step-4 \N \ St 5 \ \ H ep- R R N H 16 a-g Ex102-108 Step-1 To a solution of nitrile 12a-g (1.0 eq.) in ethyl acetate (20 Vol.) was added sodium metal (2.0 eq.) portion wise at 0-5 0C under nitrogen here. The reaction mixture was stirred at room temperature for 6 h. The progress of the reaction was monitored by TLC. After W0 2015/110491 59 completion, the reaction mixture was cooled to 0-5°C followed by quenching with ol (5 Vol.) and the solvent was evaporated under pressure. The resultant solid was dissolved in water (10 Vol.) and washed with toluene (2 X 10 Vol.). The aqueous solution was acidified with acetic acid (pH: 4 to 5) and extracted with dichloromethane (3 X 10 Vol.). The combined organic layer was washed with water, brine, dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude material was purified by recrystallization using ethyl acetate and hexane to afford 13a-g.

Step-2 To a solution of 13a-g (1.0 eq.) in ethanol (10 Vol.) were added hydrazine monohydrochloride (1.5 eq.) and acetic acid (1.2 eq.) at room temperature under nitrogen atmosphere. The reaction mixture was heated to 85 CC and stirred for 5-6 h. The reaction was monitored by TLC. After completion of the reaction, the reaction mixture was cooled to room temperature. The reaction mixture was quenched with water (10 Vol.) and concentrated under d pressure. The resultant aqueous layer was washed with toluene (3 X 5 Vol.) and basified with 10% aq. sodium bicarbonate solution (pH: 8-9). The aqueous layer was extracted with dichloromethane (4 X 5 Vol.). ed organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to afford 14a-g.

The product obtained was used without further purification.

Step-3 To a solution of 14a-g (1.0 eq.) in acetic acid (10 Vol.) was added ethyl acetoacetate (2.0 eq.) at room temperature and heated to 105 CC for 6 h. The ss of the reaction was monitored by TLC. After completion, the reaction mass was concentrated under high vacuum at 50 oC.

The resultant solid was diluted with water and extracted with dichloromethane (3 X 2 Vol.).

The combined c t was washed with 10% sodium bicarbonate on, water and brine. The organic extract was dried over sodium sulphate, filtered and concentrated under vacuum at 50 oC. The residue obtained was treated with dichloromethane (25 mL). The solid was filtered and dried under vacuum to afford pure ISa-g.

Step-4 To a sion of 15a-g (1.0 eq.) in dry toluene (15 Vol.) were added phosphoryl chloride (1.0 eq.) and N, N—diethyl e (2.0 eq.) at room temperature under en atmosphere.

The reaction mass was heated to 105 CC for 16 h. After 16 h, the reaction mass was W0 2015/110491 60 concentrated under high vacuum at 50-55 0C and co-evaporated with toluene under high vacuum at 50-55 0C. To the residue was added water (20 Vol.) ed by extraction with dichloromethane (3 X 20 Vol.), and the combined organic layer was washed with water, brine and dried over sodium sulphate. The organic layer was concentrated under vacuum at 45-50 0C to get crude compound. The crude compound was purified by flash column chromatography to afford 16a-g.

Step-5 To a solution of 16a-g (1.0 eq.) in toluene (20 V) was added the 4-fluorobenzylamine (1.3 eq.) and DIPEA (5 V) sequentially. The reaction mixture was then heated to 90 CC and stirred well for 16 h. The ss of the reaction was monitored by TLC. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was d with water (20 V) and extracted with dichloromethane (3 X 10 V). The combined c extract was washed with water, brine, dried over sodium sulphate, filtered and trated under reduced pressure. The crude material was purified by flash column chromatography (silica gel, ethyl acetate in hexane) to afford the desired compounds with >95% HPLC purity.

EXAMPLE 109 F F F Ex9 17 Ex109 To a solution of Ex 9 (2.0 g, 4.926 mmol) in dichloromethane (50 mL) was added BBr3 (lM solution in CH2C12, 25 mL, 25 mmol) slowly at 0-5 c’C. After on, the reaction e was allowed to attain room temperature with stirring. After 4 h, the reaction mixture was quenched with methanol (40 mL). The reaction mixture was concentrated under reduced W0 2015/110491 61 pressure. The residue obtained was diluted with water (10 mL) and extracted with CHzClz (3 X 20 mL). The combined organic extract was washed with water, brine, dried over sodium sulphate, d and concentrated under reduced pressure. The crude material was purified by recrystallization in dichloromethane to afford 17 (1.8 g, 96.77%) as a brown solid.

Step-2 To a solution of 17 (1.8 g, 4.762 mmol) in DMF (36 mL) was added cesium carbonate (3.099 g, 9.51 mol) at room temperature. To this e iodoethane (7.427 g, 3.83 mL, 47.62 mmol) was added at the same temperature and stirred well. After 16 h, the reaction mixture was quenched with ice-cold water (180 mL) and extracted with ethyl acetate (3 X 20 mL). The ed organic extract was washed with water, brine, dried over sodium sulphate, filtered and concentrated under reduced pressure. The crude material was purified by flash column chromatography (silica gel, ethyl acetate in hexane as eluent) followed by recrystallization in ethyl acetate to give Ex 109 (0.9 g, 43.06%) as an off-white solid.

EXAMPLE 1 10 O\ OH N/ BBr3 N/ 4} ~/ w ~ 4} HNM HNM 1s Ex110 To a solution of 18 which was formed as described in General Procedure A (500 mg, 1.242 mmol) in dichloromethane (12.5 mL) was added BBr3 (1M on in CHzClz, 7.86 mL, 7.86 mmol) slowly at 0-5 c’C. After addition, the reaction mixture was allowed to attain room temperature with stirring. After 4 h, the reaction mixture was quenched with methanol (10 mL). The on mixture was concentrated under reduced pressure. The residue obtained was diluted with water (10 mL) and ted with CH2C12 (3 X 10 mL). The combined organic extract was washed with water, brine, dried over sodium sulphate, filtered and trated under reduced re. The crude material was purified by flash column chromatography a gel, ethyl acetate in hexane) followed by recrystallization in dichloromethane to afford Ex 110 (110 mg, 23.65%) as an off-white solid.

W0 2015/110491 62 EXAMPLE 1 1 1 \O o \ / POCI3 N / O \ / —> N —> HN O NH Step-1 Step-2 NH _ 3 19 NW/ O N F C HN4<\_/§N' EX 1 1 1 Step-1 To a solution of 3 (500 mg, 4.28 mmol) in acetic acid (10 mL) was added methyl isobutyl acetate (0.87 mL, 8.57 mol) at room ature and stirred at 105 CC for 16 h. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was concentrated under high vacuum at 50 oC. The resultant solid was d with water and extracted with dichloromethane (3 X 10 mL). The combined organic extract was washed with 10% sodium bicarbonate on, water and brine. The organic extract was dried over sodium sulphate, filtered and concentrated under vacuum to afford 19 (600 mg, 85.71%) as a brown solid.

Step-2 To a suspension of 19 (1.0 g, 3.05 mmol) in dry toluene (15 mL) were added phosphoryl chloride (7.14 mL, 76.36 mmol) and N,N—diethyl e (0.98 mL, 6.11 mol) at room temperature under nitrogen atmosphere. The reaction mass was heated to 105°C for 16 h.

After 16 h, the on mixture was concentrated under reduced pressure at 50-55 0C and co- evaporated with toluene under reduced pressure. To the resultant solid, was added water (40 mL) and extracted with dichloromethane (3 X 40 mL). The combined organic layer was washed with water, brine, dried over sodium sulphate and concentrated under reduced pressure to get crude compound. The crude compound was purified using flash column W0 2015/110491 63 chromatography (silica gel, using ethyl acetate and hexane as eluent) to afford 20 (550 mg, 52.08%) as a yellow solid.

Step-3 To the solution of 20 (500 mg, 1.445 mmol) in toluene (5 mL) were added 4-fluoro benzyl amine (0.215 mL, 1.88 mmol) and DIPEA (4 mL, 22.965 mmol), followed by heating to 90°C for 16 h. The progress of the on was monitored by TLC. After completion, the reaction mass was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with water (30 mL) extracted with dichloromethane (3 X 10 mL). The combined organic layer was washed with water, brine, dried over sodium te, filtered and concentrated under high vacuum at 45-50°C. The crude al was purified by flash column chromatography (silica gel, using ethyl acetate in hexane as eluent) to afford Ex 111 (280 mg, .92%) as a yellow solid.

EXAMPLE 1 12 HN—lil Step-1 HN—lil Step-2 l N’N\ Step-3 HZNM —’H2N \ —’ V —’ 21 22 < 23 F HN Step-5 \ \ NQ7 me , W0 10491 64 F F Step 6_ ><OJLN Step 7_ O HCI A HN O N / N N’ / N \ \ / N V7 \ \ \ \ \ N N \N \ Br \ / \ \N \N 26 27 Ex. 112 Step-1 To a solution of 21, (10 g, 102.97 mmol) in acetonitrile (250 mL), was added AIBN (1.65 g, .29 mol) at 0-5 0C. To the on mixture was slowly added N—bromosuccinimide (18.33 g, 102.97 mmol) while maintaining temperature between 0-5 0C. After the addition, the reaction mixture was allowed to attain room temperature gradually and d for 2 h. The progress of the reaction was monitored with TLC. Starting amine was completely ed.

The reaction mixture was concentrated under reduced pressure. The residue was diluted with water (100 mL) and the insoluble material was d. The filtrate was treated with 10% NaHC03 solution (100 mL) and extracted with dichloromethane (3 X 100 mL). The combined organic extract was washed with water, saturated brine and dried over sodium sulphate. The organic layer was filtered and dried under reduced pressure. The crude material ed was purified by flash column chromatography (Silica gel, 30% Ethyl acetate in hexane) to afford 22 (14.0 g, 77.25%) as a brown solid.

Step-2 To a solution of 22 (14.0 g, 79.54 mmol) in ethanol (280 mL) were added ethyl acetoacetate (15.15 mL, 15.59 g, 119.79 mmol) and acetic acid (4.55 mL, 79.54 mol) at room temperature under nitrogen atmosphere. The reaction mixture was then heated to 85 °C and stirred for 16 h. The progress of the reaction was monitored by TLC. After 16 h, the reaction mixture was concentrated completely under reduced pressure. The resultant solid was treated with CHzClz (30 mL) and the solid was filtered. The d solid was dried under high vacuum at 45-55 0C to afford 23 (10.7 g, 55.57%) as a pale yellow solid.

W0 2015/110491 65 Step-3 To a suspension of 23 (10.5 g, 43.38 mmol) in toluene (157.5 mL) were added N,N—diethyl aniline (20.63 mL, 130.16 mmol) and phosphorous oxychloride (10.14 mL, 108.47 mmol) at room temperature. The reaction mixture was heated to 105 CC for 16 h. The progress of the reaction was monitored by TLC. After 16 h, the on mass was cooled to room temperature and ed with saturated brine solution, and filtered through Celite bed. The layers were separated and the toluene layer was washed with saturated sodium bicarbonate solution and saturated brine solution. The organic layer was dried over sodium sulphate, filtered and concentrated to get crude material. The crude material was d by flash column chromatography a gel, 5-10% Ethyl acetate in Hexane) to get 24 (10.0 g, 88.49%) as a pale yellow solid.

Step-4 To a solution of 24 (10.0 g, 38.38 mmol) in acetonitrile (100 mL) were added 4-fiuoro benzyl amine (5.27 mL, 46.06 mmol) and DIPEA (32.85 mL, 191.9 mol) at room temperature. The reaction mixture was heated to 80 0C for 16 h. The progress of the reaction was monitored by TLC. After 16 h, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resultant solid was d with water (100 mL) and extracted with ethyl e (3 X 100 mL). The combined organic layer was washed with water, brine, dried over sodium te. The organic layer was filtered and concentrated under reduced pressure to get crude compound. The crude material was purified by flash column chromatography (Silica gel, 5-10% Ethyl acetate in Hexane) to afford 25 (12.0 g, 89.55%) as a colorless solid.

Step-5 To a solution of 25 (2.0 g, 5.727 mmol) in dichloromethane (30 mL) were added DMAP (34.98 mg, 0.286 mmol), Boc-anhydride (1.44 mL, 6.30 mol) at 10-15 0C under nitrogen atmosphere. The reaction mixture was slowly warmed to room temperature and d for 6 h.

The progress of the reaction was monitored by TLC. After completion, the reaction mixture was cooled to 0-5°C and quenched with water. The mixture was extracted with CH2C12 (3 X mL). The combined organic layer was washed with brine, dried over sodium sulphate, d and concentrated under reduced pressure. The crude compound was purified by recrystallization using CH2C12 and Hexane solvent combination to afford 26 (2.12 g, 82.38%) as an off-white solid.

W0 2015/110491 66 2015/051177 Step-6 To a solution of 26 (500 mg, 1.113 mmol) in DME : water (5:1, 10 mL) were added 4- pyridine boronic acid (205.23 mg, 1.66 mmol) and cesium carbonate (1.088 mg, 3.339 mmol) at room temperature under argon here. The reaction mixture was ed thoroughly with argon. To the reaction mixture was added Pd(PPh3)4 (258 mg, 0.0445 mmol) under argon atmosphere. The reaction mixture was stirred for 3 h at 100 0C under microwave condition.

The progress of the reaction of was monitored by LCMS. The reaction mixture was diluted with water and extracted with ethyl acetate (3 X 10 mL). The combined organic layer was washed with brine and dried over sodium sulphate. The organic layer was concentrated under reduced pressure to get crude material. The crude compound was purified by flash column chromatography to get 27 (0.2 g, 40%) as a brown semi solid.

Step-7 To a solution of 27 (200 mg) in 1,4-dioxane (2 mL) was added HCl solution (15 mL, 4M in dioxane) at 10-15 c’C under nitrogen atmosphere. The reaction e was stirred for 16 h at room ature. The solid formed was filtered. The solid was again dissolved in water (4 mL) and the insoluble material was filtered. The filtrate was concentrated under reduced pressure to get Ex. 112 in the salt form (60 mg, 35%) as a pale yellow solid.

Analytical data for the compounds of Examples 72-112 are shown in Table 3.

Table 3 Ex. Analytical Data (MeOD, 300 MHz): 5 7.65 (dd, 4 H), 7.26 (d, 2 H), 7.13 (d, 1 H), 7.05 (d, 72 1 H), 5.92 (s, 1 H), 4.79 (s, 2 H), 3.89 (s, 6 H), 2.53 (s, 3 H), 2.37 (s, 3 H), LCMS : 457.2 [M+H], HPLC purity: 98.46% 1H-NMR (MeOD, 300 MHz): 5 7.79 (d, 2 H), 7.67 (d, 2 H), 7.30 (d, 1 H), 7.15 (d, 73 1 H), 7.08 (d, 1H), 6.45 (s, 1 H), 3.90 (s, 6 H), 2.58 (s, 3 H), 2.47 (s, 3 H), LCMS : 443.2 [M+H], HPLC purity: 99.99% 1H-NMR (MeOD, 300 MHz): 5 8.53 (d, 2 H), 7.37 (d, 1 H), 7.22 (m, 2 H), 7.09 (m, 74 3 H), 3.90 (s, 6 H), 2.70 (s, 3 H), 2.58 (s, 3 H), LCMS : 376.5 [M+H], HPLC purity: 95.69% W0 2015/110491 67 2015/051177 EX. Analytical Data 1H—NMR (MeOD, 300 MHz): 5 8.52 (d, 2 H), 7.48 (d, 2 H), 7.26 (d, 1 H), 7.14 (d, 75 1 H), 7.09 (dd, 1 H) 5.90 (s, 1 H), 4.78 (s, 2 H), 3.89 (s, 6 H), 2.54 (s, 3 H), 2.37 (s, 3 H), LCMS : 390.6 [M+H], HPLC purity: 98.97% 1H-NMR(MeOD, 300 MHz): 5 7.51 (d, 2 H), 7.25 (dd, 2 H), 7.12 (d, 1 H), 7.06 (q, 76 1 H), 5.93 (s, 1 H), 4.70 (s, 2 H), 3.88 (s, 6 H), 2.51 (s, 3 H), 2.37 (s, 3 H), LCMS : 473.7 [M+H], HPLC purity: 100% 1H—NMR (MeOD, 300 MHz): 5 7.56 (d, 2 H), 7.38 (d, 2 H), 7.25 (s, 1 H), 7.09 (m, 77 2 H), 5.95 (s, 1 H), 4.63 (s, 2 H), 3.88 (s, 6 H), 2.52 (s, 3 H), 2.39 (s, 3 H), 2.12 (s, 3 H), LCMS ; 446.5 [M+H], HPLC purity: 99.56% 1H-NMR(MeOD, 400 MHz): 5 7.23 (q, 3 H), 7.08 (dd, 1 H), 7.02 (d, 1 H), 6.77 78 (dd, 2 H), 5.97 (s, 1 H), 4.52 (s, 2 H), 3.86 (s, 6 H), 2.91 (s, 3 H), 2.48 (s, 3 H), 2.37 (s, 3 H), LCMS : 432.5 [M+H], HPLC purity: 99.59% 1H—NMR (MeOH, 400 MHz): 5 8.19 (s, 1 H), 7.74 (dd, 1 H), 7.23 (s, 1 H), 7.09 (dd, 1 H), 7.02, (d, 1 H), 6.88 (d, 1 H), 6.00 (s, 1 H), 4.60 (s, 2 H), 3.89 (s, 3 H), 3.86 (s, 3 H), 2.48 (s, 3 H), 2.39 (s, 3 H), LCMS ; 420.4 [M+H], HPLC purity: 99.86% 1H-NMR(MeOH, 400 MHz): 5 7.39 (d, 2 H), 7.23 (m, 3 H), 7.09 (dd, 1 H), 7.02 80 (d, 1 H), 5.94 (s, 1 H), 4.62 (s, 2 H), 3.86 (s, 6 H), 2.93 (s, 3 H), 2.49 (s, 3 H), 2.36 (s, 3 H), LCMS ; 482.5 [M+H], HPLC purity: 99.20% 1H-NMR(MeOH, 400 MHz): 5 7.23 (m, 3 H), 7.09 (dd, 1 H), 7.02 (d, 1 H), 6.77 81 (dd, 2 H), 5.96 (s, 1 H), 4.54 (s, 2 H), 3.86 (s, 6 H), 2.48 (s, 3 H), 2.37 (s, 3 H), LCMS : 405.6 [M+H], HPLC purity: 99.74% 1H-NMR (DMSO, 400 MHz): 5 8.57 (t, 1 H), 8.02 (s, 1 H), 7.82 (d, 1 H), 7.76 (d, 1 H), 7.63 (t, 1 H), 7.21 (dd, 1 H), 7.01 (d, 1 H), 6.05 (s, 1 H), 4.70 (d, 2 H), 3.78 (s, 6 H), 3.20 (s, 3 H), 2.55 (s, 3 H), 2.37 (s, 3 H), LCMS : 467.4 [M+H], HPLC purity: 99.78% 1H-NMR(MeOH, 400 MHz): 5 8.21 (d, 2 H), 7.47 (d, 2 H), 7.14 (d, 1 H), 7.01 (dd, 83 1H), 6.94 (d, 1 H), 5.83 (s, 1 H), 4.50 (s, 2 H), 3.78 (s, 6 H), 2.42 (s, 3 H), 2.28 (s, 3 H), LCMS : 406.5 [M+H], HPLC purity: 98.91% 1H—NMR (MeOH, 400 MHz): 5 7.97 (dd, 2 H), 7.69 (d, 2 H), 7.26. (d, 1 H), 7.12 84 (dd, 1H), 7.05 (d, 1 H), 5.93 (s, 1 H), 4.82 (s, 2 H), 3.90 (s, 6 H), 3.13 (s, 3 H), 2.54 (s, 3 H), 2.38 (s, 3 H), LCMS : 467.3 [M+H], HPLC purity: 99.93% W0 2015/110491 63 EX. Analytical Data 1H—NMR (MeOH, 300 MHz): 5 8.83 (d, 1 H), 8.63 (m, 1 H), 8.13 (d, 1 H), 8.04 (t, 85 1 H), 7.13 (d, 1H), 7.02 (111,2 H), 6.70 (s, 1H) 4.15 (t, 2 H), 3.92 (d, 6 H), 3.57 (t, 2 H), 2.64 (s, 3 H), 2.43 (s, 3 H), LCMS : 404.3 [M+H], HPLC purity: 99.88% 1H—NMR (MeOH, 300 MHz): 5 7.43 (dd, 2 H), 7.35 (d, 2 H), 7.52 (d, 1 H), 7.10 86 (dd, 1 H), 7.04 (d, 1H), 5.96 (s, 1H) 4.64 (s, 2 H), 3.89 (d, 6 H), 2.51 (s, 3 H), 2.39 (s, 3 H), 1.30 (s, 9 H), LCMS : 445.4 [M+H], HPLC purity: 99.03% 1H—NMR (MeOH, 300 MHz): 5 8.60 (d, 1 H), 7.30 (d, 1 H), 7.24 (d, 1 H), 7.10 (dd, 87 1 H), 7.02 (d, 1H), 5.91 (s, 1H) 4.74 (s, 2 H), 3.87 (d, 6 H), 2.71 (s, 1 H), 2.51 (s, 3 H), 2.37 (s, 3 H), LCMS : 405.4 [M+H], HPLC purity: 98.34% 1H—NMR (MeOH, 300 MHz): 5 7.24 (m, 2 H), 7.09 (d, 1 H), 7.04 (d, 1 H), 6.95 (m, 88 2 H), 5.96 (s, 1H) 3.89 (d, 6 H), 3.73 (t, 2 H), 3.26 (t, 2 H), 2.49 (s, 3 H), 2.41 (s, 3 H), LCMS : 409.3 [M+H], HPLC purity: 98.81% 1H—NMR (MeOH, 300 MHz): 5 8.80 (d, 2 H), 8.10 (d, 2 H), 7.11 (d, 1 H), 6.97 (m, 89 2 H), 6.60 (s, 1H) 4.07 (t, 2 H), 3.87 (d, 6 H), 3.43 (t, 2 H), 2.59 (s, 3 H), 2.41 (s, 3 H), LCMS : 404.4 [M+H], HPLC : 99.23% 1H-NMR(MeOH, 300 MHz): 5 10.69 (s, 1 H), 9.00 (s, 1 H), 8.45 (dd, 1 H), 8.31 90 (d, 1 H), 7.77 (s, 1 H), 7.40 (d, 1 H), 7.25 (dd, 1H), 7.06 (d, 1H), 3.81 (d, 6 H), 2.67 (s, 3 H), 2.49 (s, 3 H), LCMS : 377.3 [M+H], HPLC purity: 99.91% 1H-NMR(MeOH, 300 MHz): 5 7.27 (dd, 2 H), 7.22 (d, 1 H), 7.17 (dd, 2 H), 7.08 91 (dd, 1 H), 7.02 (d, 1H), 6.17 (s, 1H) 4.62 (m, 1 H), 3.49 (dd, 2 H), 3.10 (dd, 2 H), 2.46 (s, 3 H), 2.44 (s, 3 H), LCMS : 415.4 [M+H], HPLC purity: 99.94% 1H-NMR(MeOH, 300 MHz): 5 8.49 (d, 1 H), 7.80 (dd, 1 H), 7.30 (d, 1 H), 7.25 (d, 92 1 H), 7.10 (dd, 1H), 7.05 (d, 1H), 5.99 (s, 1H) 4.70 (s, 2 H), 3.89 (d, 6 H), 2.53 (s, 3 H), 2.51 (s, 3 H), 2.39 (s, 3 H), LCMS : 404.3 [M+H], HPLC purity: 99.93% 1H-NMR(MeOH, 300 MHz): 5 11.52 (s, 1 H), 7.69 (s, 1 H), 7.40 (d, 1 H), 7.23 (m, 93 2 H), 7.04 (d, 1H), 3.80 (d, 6 H), 2.54 (s, 3 H), 2.49 (s, 3 H), 2.38 (s, 3 H), LCMS : 396.3 [M+H], HPLC purity: 98.52% 1H-NMR(MeOH, 400 MHz): 5 7.96 (dd, 2 H), 7.52 (d, 2 H), 7.20 (d, 1 H), 7.08 94 (dd, 1 H), 7.00 (d, 1H), 5.86 (s 1 H), 4.72 (s, 2 H), 3.85 (d, 6 H), 2.56 (s, 3 H), 2.49 (s, 3 H), 2.32 (s, 3 H), LCMS : 431.3 [M+H], HPLC purity: 99.66% W0 2015/110491 69 EX. Analytical Data 1H—NMR (MeOH, 300 MHz): 5 8.60 (d, 1 H), 7.37 (s, 1 H), 7.32 (d, 1 H), 7.16 (d, 95 1 H), 7.07 (d, 1H), 6.61 (s 1 H), 3.91 (d, 6 H), 2.58 (s, 3 H), 2.55 (s, 3 H), LCMS : 366.4 [M+H], HPLC purity: 94.2% 1H-NMR (MeOH, 300 MHz): 5 8.13 (d, 1 H), 7.92 (d, 1 H), 7.85 (d, 1 H), 7.56 (m, 3 H), 7.43 (d, 1 H), 7.24 (d, 1 H), 7.11 (dd, 1 H), 7.02 (d, 1 H), 6.01 (s, 1 H), 5.12 (s, 2 H), 3.86 (d, 6 H), 2.47 (s, 3 H), 2.36 (s, 3 H), LCMS : 439.5 [M+H], HPLC purity: 99.94% (DMSO, 400 MHz): 5 8.50 (t, 1 H), 7.78 (d, 2 H), 7.55 (d, 2 H), 7.38 (d, 97 1 H), 7.30 (s, 2 H), 7.22 (dd, 1H), 7.00 (d, 1H), 5.94 (s, 1 H), 5.12 (s, 2 H), 3.78 (d, 6 H), 2.54 (s, 3 H), 2.32 (s, 3 H), LCMS : 468.3 [M+H], HPLC purity: 98.74% 1H-NMR(MeOD, 400 MHz): 5 8.16 (dd, 2 H), 7.19 (dd, 2 H), 7.24 (d, 1 H), 7.10 98 (d, 1 H), 7.02 (d, 1H), 5.72 (s, 1H), 4.99 (q, 1H), 3.87 (s, 6 H), 2.66 (s, 1 H), 2.50 (s, 3 H), 2.32 (s, 3 H), LCMS : 404.5 [M+H], HPLC purity: 97.3% 1H-NMR(DMSO, 400 MHz): 5 8.55 (t, 1 H), 7.77 (d, 1 H), 7.70 (d, 1 H), 7.46 (dd, 99 2 H), 7.16 (dd, 2 H), 6.97 (d, 1H), 6.08 (s, 1H), 4.58 (d, 1 H), 3.82 (s, 3 H), 3.75 (s, 3 H), 2.39 (s, 3 H), LCMS : 393.4 [M+H], HPLC purity: 99.61% 1H-NMR(DMSO, 400 MHz): 5 8.62 (t, 1 H), 8.58 (s, 1 H), 8.51 (dd, 2 H), 7.78 (d, 100 1 H), 7.72 (dd, 1 H), 7.36 (d, 2 H), 6.97 (d, 1H), 6.02 (s, 1H), 4.65 (d, 2 H), 3.82 (s, 3 H), 3.75 (s, 3 H), 2.38 (s, 3 H), LCMS : 376.4 [M+H], HPLC purity: 96.46% 1H-NMR (DMSO, 400 MHz): 8 8.69 (t, 1 H), 8.58 (s, 1 H), 8.03 (s, 1 H), 7.84 (d, 1 H), 7.78 (t, 2 H), 7.71 (dd, 1 H), 7.64 (t, 1H), 6.98 (d, 1 H), 6.14 (s, 1H), 4.73 (d, 2 H), 3.83 (s, 3 H), 3.76 (s, 3 H), 3.21 (s, 3 H), 2.41 (s, 3 H), LCMS : 453.3 [M+H], HPLC purity: 98.50% 1H-NMR (MeOD, 300 MHz): 5 7.43 (q, 2 H), 7.09 (m, 3 H), 7.00 (dd, 1 H), 6.89 102 (d, 1 H), 5.95 (t, 3 H), 4.64 (s, 2 H), 2.47 (s, 3 H), 2.36 (s, 3 H), LCMS : 391.6 [M+H], HPLC purity: 99.74% 1H-NMR (MeOD, 300 MHz): 5 7.87 (d, 1 H), 7.59 (m, 2 H), 7.43 (dd, 2 H), 7.08 (t, 103 2 H), 5.99 (s, 1 H), 4.64 (s, 2 H), 2.54 (s, 3 H), 2.40 (s, 3 H), LCMS : 415.4 [M+H], HPLC purity: 99.90% 1H-NMR (MeOD, 300 MHz): 5 7.89 (d, 2 H), 7.72 (d, 2 H), 7.46 (m, 2 H), 7.11 (m, 104 2 H), 6.01 (s, 1 H), 4.67 (s, 2 H), 2.59 (s, 3 H), 2.41 (s, 3 H), LCMS : 415.1 [M+H], HPLC purity: 99.92% W0 2015/110491 70 Ex. Analytical Data 1H-NMR(MeOD, 300 MHz): 5 7.45 (t, 2 H), 7.11 (d, 2 H), 6.91 (s, 2 H), 5.97 (s, 1 105 H), 4.67 (s, 2 H), 3.90 (s, 6 H), 3.82 (s, 3 H), 2.56 (s, 3 H), 2.39 (s, 3 H), LCMS : 437.2 [M+H], HPLC purity: 99.63% 1H-NMR(MeOD, 300 MHz): 5 7.60 (m, 1 H), 7.43 (m, 3 H), 7.31 (m, 1 H), 7.09 106 (m, 2 H), 5.98 (s, 1 H), 4.65 (s, 2 H), 2.54 (s, 3 H), 2.40 (s, 3 H), LCMS : 383.5 [M+H], HPLC : 99.88% 1H—NMR (MeOD, 300 MHz): 5 8.09 (d, 2 H), 7.84 (d, 2 H), 7.45 (dd, 2 H), 7.10 (t, 107 2 H), 6.01 (s, 1 H), 4.67 (s, 2 H), 3.93 (s, 3 H), 2,59 (s, 3H), 2.42 (s, 3 H), LCMS : 404.45 [M+H], HPLC purity: 99.62% 1H—NMR (MeOH, 300 MHz): 5 7.42(d, 1 H), 7.34 (m, 3 H), 7.18 (m, 3 H), 5.95 (s, 108 1 H), 4.62 (s, 2 H), 3.92 (s, 3 H), 2.51 (s, 3 H), 2.39 (s, 3 H), 2.34 (s, 3 H), LCMS : 391.5 [M+H], HPLC : 98.09% 1H-NMR(MeOD, 300 MHz): 5 8.43 (t, 1 H), 7.44 (m, 2 H), 7.38 (s, 1 H), 7.16 (m, 109 3 H), 6.99 (d, 1 H), 6.00 (s, 1 H), 4.57 (d, 2 H), 4.04 (m, 4 H), 2.51 (s, 3 H), 2.32 (s, 3 H), 1.35 (q, 6 H), LCMS : 435.3 [M+H], HPLC purity: 99.75% 1H-NMR(DMSO, 400 MHz): 5 8.82 (bs, 2 H), 8.33 (bs, 1 H), 7.28 (d, 2 H), 7.14 110 (t, 3 H), 6.92 (dd, 1 H), 6.77 (d, 1 H), 5.91 (s, 1 H), 4.53 (s, 2 H), 2.48 (s, 3 H), 2.30 (s, 3 H), 2.26 (s, 3 H), LCMS : 375.3 [M+H], HPLC purity: 99.70% 1H-NMR(MeOH, 400 MHz): 5 7.40 (s, 1 H), 7.35 (t, 2 H), 7.07. (dd, 1 H), 6.99 (t, 111 2H), 6.92 (d, 1 H), 5.81 (s, 1 H), 4.55 (s, 2 H), 3.78 (d, 6 H), 2.81 (m, 1 H), 2.45 (s, 3 H), 1.13 (d, 6 H), LCMS : 435.5 [M+H], HPLC purity: 95.7% 1H—NMR (MeOD, 400 MHz): 5 8.88 (d, 2 H), 7.57 (d, 2 H), 7.49 (m, 2 H), 7.13 (t, 112 2 H), 6.65 (s, 1 H), 4.86 (s, 2 H), 2.71 (s, 3 H), 2.67 (s, 3 H), LCMS : 412.4 [M+H], HPLC purity: 99.49% BIOLOGICAL ASSAYS In vitro assay in mammalian cell culture The antiviral activity of compounds ofthe invention has been evaluated based on the ability ofthe compounds to prevent virus from causing viral cytopathic s (CPE) in mammalian cell culture. Incubation time, cell line, cell density and virus titer differed from assay to assay but the general procedure was as follows: Cells were cultivated on 96 well flat bottom plates to imately 90 % confluence (20 000-90 000 cells/well) in a suitable media. The titer of W0 2015/110491 71 2015/051177 the Virus was determined by the standard method of tissue culture infective dose o) on cells. Briefly, cells were infected with 50 ul of Virus suspension, and diluted 10-fold in media.

The plates were incubated in 37 0C with 5 % C02 for 3-7 days and cells were inspected daily for CPE. After ining CPE, plates were stained with Gram’s Crystal Violet solution and l density was read at 540 nm. The highest Virus dilution that resulted in > 95 % CPE was used in the assays. Substances at a final concentration of 2.5-20 uM and the Virus were added to the cells and incubated for 3-7 days depending on the Virus and cell line used. As controls, cted cells and cells infected with Virus (no substance) were included on each plate. The cells were stained with crystal Vio let after determining the CPE on infected controls and the optical density was read at 540 nm. The inhibition capacity was calculated as a % by comparison with non-infected and infected controls.

Table 4 shows the inhibition capacity of compounds of the invention on different picomaViruses at different concentrations. LV012: Ljungan Virus strain 012; LV145: n Virus strain 145; EMCV: encephalomyocarditis Virus; HPeV-l: Human ovirus strain 1; HPeV-2: Human parechovirus strain 2; PTV: Porcine Tescho Virus; EV6: Enterovirus strain 6; EV30: Enterovirus strain 30; EV71: virus strain 71; Cox-B1: coxsackie B Virus strain 1; Cox-B2: coxsackie B Virus strain 2; Cox-B3: coxsackie B Virus strain 3; Cox-B4: coxsackie B Virus strain 4; Cox-B5: coxsackie B Virus strain 5; Poliol: polio Virus strain 1.

Table 4 EX. Virus Conc. uM % inh. Ex. Virus Conc. uM % inh. 1 EV6 0.25 75 57 HPeV-l 10.0 22 2 EV30 0.25 85 58 Polio-1 0.1 74 3 EMCV 2.5 92 59 Cox-B2 10.0 88 4 EV71 2.5 46 60 EV-71 1.0 69 Cox-B4 0.25 71 61 LV0145 10.0 85 6 LV145 5.0 56 62 Polio-1 1.0 97 7 LV145 2.5 54 63 Polio-1 1.0 87 8 Cox-B5 0.25 100 64 Polio-1 1.0 20 9 EV71 0.25 93 65 Cox-B2 1.0 91 LV145 2.5 69 66 Polio-1 0.01 100 11 PTV 2.5 57 67 Polio-1 1.0 63 W0 2015/110491 72 2015/051177 EX. Virus Conc. ”M % inh. Ex. Virus Conc. ”M % inh. 12 LV012 2.5 60 68 LV145 10.0 86 13 EV71 1 66 69 Cox-B2 10.0 65 14 Polio-1 10.0 73 70 Polio-1 10.0 89 Polio-1 10.0 75 71 Polio-1 10.0 72 16 LV145 10.0 83 72 Cox-B4 0.1 85 17 LV145 10.0 75 73 Cox-B4 0.1 44 18 Polio-1 10.0 51 74 LV012 10 55 19 LV145 10.0 34 75 Cox-B3 0.01 85 EV71 1.0 40 76 Cox-B3 1 100 21 Polio-1 10.0 78 77 Cox-B3 0.1 60 22 Cox-B2 10.0 44 78 Cox-B1 0.1 94 23 Polio-1 10.0 94 79 EV68 1 51 24 Polio-1 10.0 86 80 EV6 1 93 HPeV-l 10.0 24 81 Cox-B1 0.01 76 26 Cox-B2 10.0 30 82 Cox-B3 0.01 82 27 Polio-1 10.0 35 83 EV71 0.01 82 28 Polio-1 10.0 72 84 Cox-B3 0.1 84 29 Cox-B2 10.0 62 85 Cox-B1 1 98 LV145 10.0 100 86 LV012 10 48 31 LV145 10.0 14 87 Polio-1 0.1 100 32 Polio-1 10.0 25 88 EV30 1 88 33 EV30 1.0 48 89 Cox-2 1 100 34 EV71 1.0 100 90 LV012 10 71 EV30 0.1 88 91 Cox-B5 1 75 36 Cox-B5 1.0 97 92 Cox-B3 0.01 100 37 Cox-B2 10.0 78 93 LV012 100 42 38 LV0145 10.0 84 94 Cox-B1 0.01 100 39 Polio-1 1.0 71 95 HPeV-l 10 55 40 EV71 0.01 100 96 Cox-B1 0.1 100 41 EMCV 10.0 93 97 EV71 0.1 94 42 Polio-1 1.0 96 98 Not tested - - 43 HPeV-l 10.0 46 99 Cox-B3 0.1 100 EX. Virus Conc. uM % inh. Ex. Virus Conc. uM % inh. 44 Polio-1 1.0 70 100 EV30 0.1 78 45 EV71 1.0 100 101 EV71 0.1 99 46 LV0145 10.0 92 102 Cox-B3 1 100 47 HPeV-l 10.0 56 103 EMCV 10 74 48 Polio-l 1.0 79 104 Theiler 10 59 49 Cox-B2 1.0 80 105 EV30 10 67 50 Polio-1 1.0 81 106 LV145 10 100 51 LV0145 10.0 94 107 Polio 1 21 52 LV0145 10.0 63 108 Cox-B1 1 100 53 Polio-1 10.0 84 109 1 1 88 54 Polio-1 1.0 89 110 Cox-B5 1 72 55 LV145 1.0 41 111 Cox-B1 0.1 68 56 LV145 1.0 61 Table 5 and 6 show the antiviral effect of certain compounds of the invention at different concentrations against a panel of different viruses. LV012: Ljungan Virus strain 012; LV145: Ljungan Virus strain 145; EMCV: encephalomyocarditis Virus; HPeV-l: Human parechovirus strain 1; : Human parechovirus strain 2; PTV: Porcine Tescho Virus; EV6: Enterovirus strain 6; EV30: Enterovirus strain 30; EV71: Enterovirus strain 71; B1: coxsackie B Virus strain 1; B2: coxsackie B Virus strain 2; B3: coxsackie B Virus strain 3; B4: coxsackie B Virus strain 4; B5: coxsackie B Virus strain 5; Poliol: polio Virus strain 1.

Table 5 Ex. Conc.

LV012 LV145 EMCV HPeV-l PTV EV6 EV30 1 5 34 37 14 14 19 90 100 2 5 49 17 0 0 33 83 91 4 10 28 61 81 7 87 0 0 5 18 60 0 22 11 80 58 6 10 28 63 0 60 62 58 44 7 2.5 14 54 0 6 29 78 89 8 5 38 28 0 14 22 88 53 WO 10491 74 Ex. Conc.

LV012 LV145 EMCV HPeV-l PTV EV6 EV30 9 10 18 59 14 19 23 66 35 10 0 41 25 3 43 93 88 11 10 18 77 0 8 51 70 80 12 2.5 60 nd 0 8 0 63 84 33 10 nd 69 60 13 nd nd 85 72 1 0 7 0 4 11d 77 100 75 0.1 0 0 0 0 11d 90 100 79 0.1 0 0 0 0 11d 0 10 80 1 0 0 0 0 11d 80 90 81 0.1 0 0 0 0 11d 62 97 82 0.1 0 0 0 nd nd 89 94 92 0.1 0 0 0 nd nd nd 100 94 0.1 12 0 0 nd nd nd 96 100 0.1 0 0 0 nd nd 88 78 101 0.1 0 0 0 nd nd 44 89 111 1 0 0 0 nd nd 89 80 Table 6 Ex. Conc.

EV68 EV71 B1 B2 B3 B4 B5 Polio 1 1 5 11d 44 93 60 95 86 90 31 2 5 11d 73 91 93 97 86 91 90 4 10 nd 69 36 0 0 53 0 17 5 11d 77 79 76 nd 97 94 68 6 10 nd 37 35 82 nd 69 54 19 7 2.5 11d 82 77 92 nd 82 68 80 8 5 11d 82 100 nd 89 100 91 9 10 nd 16 53 76 nd 48 73 91 10 nd 58 79 97 nd 94 92 94 11 10 nd 47 93 85 nd 100 70 52 12 2.5 11d 80 93 nd nd 77 82 73 W0 2015/110491 75 EX' com EV68 EV71 B1 132 B3 B4 B5 Polio 1 33 10 nd 0 11d 81 nd nd 92 58 72 1 nd 84 100 94 99 91 99 100 75 0.1 31 85 100 100 89 100 98 100 79 0.1 46 88 88 84 87 78 98 79 80 1 30 78 78 96 78 78 97 85 81 0.1 29 86 85 88 87 77 81 89 82 0.1 24 85 95 98 91 100 89 100 92 0.1 nd 100 100 96 100 nd 95 98 94 0.1 nd 100 100 100 100 nd 56 100 100 0.1 nd 81 nd 99 199 nd 90 83 101 0.1 nd 99 nd 99 90 nd 29 100 111 1 40 96 97 96 100 98 99 100 Evaluation of anti-viral efficacy against Coxsackie virus in a neutropenic Mouse model Test system Male BALB/c mice, weighing 22-26 grams were used with 4 animals/group.

Neutropenic ion: hosphamide Challenge organism: Coxsackie (human origin) virus CVB3 Route of infection: Intraperitoneal Route of administration: per oral End point: Cumulative survival All experimental procedures involving animals were med according to protocols approved by the Institutional Animal Ethics Committee ofAnthem Bio es. The mice, male BALB/c mice were housed 4 animals per cage and allowed access to feed and water ad libitum under controlled conditions. Mice were acclimatized for 7 days prior to the study. The animals were observed daily for general health during this period.

Neutropenic induction 4 mice/group were treated with eritoneal injection of cyclophosphamide (150 mg/kg), 2 days before and, on day “0” 4 hours before infection in order to become neutropenic.

W0 2015/110491 76 Infection and treatment Animals were infected by intraperitoneal ion of 0.2 mL of saline containing 103 PFU of Coxsackie B3 virus, Nancy strain on day 0. The s were then treated with the nd of Ex. 9, 200 mg/kg once daily per orally ng on day 1 (group 1) or on day 3 (group 2).

The control group was treated with vehicle only (0.4% Tween 80, 2% glycerol and 15% B- hydroxypropyl cyclodextrin) Clinical observation The animals were ed daily during the study period for signs of mortality, morbidity (paralysis) and signs of acute toxicity. Abnormal clinical signs were recorded if observed.

Results The results of the above described assay indicate that the compound of Ex. 9 has an antiviral effect in vivo and can extend the life of the animals, cf. Figure 1.

Toxicity Assay Mouse ent with Ex 9 at 200 and 400 mg/kg body weight/day for 7 days in BALB/C mice did not reveal any adverse clinical signs or mortality in neither sex. The treatment resulted in no adverse effects on body weight, feed consumption, hematology, clinical chemistry and histopathology ofthe major organs evaluated.

In light of above findings from the present study, the No Observed Adverse Effect Level (NOAEL) ofEx 9 could be ined as 400 mg/kg body weight/day when administered orally to BALB/c mice for 7 utive days under the tested dose levels and experimental conditions employed.

MTD study Single dose treatment with Ex 9 in doses up to 2000 mg/kg resulted in no adverse effects on clinical signs, mortality, body weight, body weight gain, feed consumption, absolute and relative organ weights. On macroscopic examination, no treatment related gross pathological findings were observed.

W0 2015/110491 77 2015/051177 In the light of the above findings, the maximum tolerable dose of Ex 9 in female Sprague Dawley rats is found to be >2000 mg/kg body weight under the experimental conditions employed. 7 days toxicity study Treatment with test item Ex 9 at 250 and 750 mg/kg body weight/day for 7 days in Sprague Dawley rats did reveal adverse clinical signs in both sexes at 750 mg/kg and mortality in one female at 750 mg/kg. The treatment resulted in adverse effects on body weight, feed consumption, logy, clinical chemistry and histopathology ofthe major organs ted at the 759 mg/kg dose level.

In light of above findings from the present study, the No ed Adverse Effect Level (NOAEL) of Ex 9 could be determined as 250 mg/kg body weight/day when administered orally to Sprague Dawley rats for 7 consecutive days under the tested dose levels and experimental ions employed. 28 days toxicity study Treatment with the test item Ex 9 at 100 and 200 mg/kg body weight for 28 days in both sexes had no adverse effects on clinical signs, body weight, feed ption, hematology, clinical chemistry, urinalysis, neurological examination, gross necropsy and histopathological evaluation of the specified tissues. All the animals survived until the scheduled terminal necropsy on Day 29. Serum mistry showed an increase in cholesterol, which was correlated with findings of macrovesicular fatty changes in liver at 200 mg/kg body weight in both the sexes.

In light of above findings from the present study, the No Observed Adverse Effect Level (NOAEL) of Ex 9 could be determined as 200 mg/kg body weight when administered orally to Sprague Dawley rats for 28 consecutive days under the tested dose levels and experimental conditions employed.

Claims (24)

What we claim is:

1. A pharmaceutical composition sing a compound of formula (Ie) or a pharmaceutically acceptable salt thereof, wherein R1 is methyl; each R2 is methoxy; R3 is methyl; m is an integer of from 0 to 2; each R4 is independently selected from C1-C6 alkyl, R12O, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, )2-, R21C(O)-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl; R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is ally substituted by one or more F; or two R4 attached to adjacent atoms of ring B form, together with the atoms to which they are attached, a 5- or ered heterocyclic or carbocyclic ring, or a benzene ring; and ring B is 5- or 6-membered heteroaryl or phenyl.

2. The composition according to claim 1, wherein ring B is .

3. The composition according to claim 1, wherein ring B is 5- or 6-membered heteroaryl.

4. A composition according to claim 1, comprising a compound selected from N-[(4-chlorophenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo[1,5-a]pyrimidinamine, N-(1,3-benzodioxolylmethyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-fluorophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, N-benzyl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[[4-(trifluoromethyl)phenyl]methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(4-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]pyrazolo[1,5- a]pyrimidinamine, [[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]acetamide, 3-(3,4-dimethoxyphenyl)-N-[(4-dimethylaminophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(6-methoxypyridyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, N-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]methanesulfonamide, -(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenol, -dimethoxyphenyl)-2,5-dimethyl-N-[(3-methylsulfonylphenyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(1-oxidopyridiniumyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(4-methylsulfonylphenyl)methyl]pyrazolo[1,5- a]pyrimidinamine, N-[(4-tert-butylphenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(2-methylpyrimidinyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(6-methylpyridyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 1-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]ethanone, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(1-naphthylmethyl)pyrazolo[1,5-a]pyrimidin amine, and 4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]benzenesulfonamide, or a pharmaceutically acceptable salt f.

5. A compound of formula (Ie) or a pharmaceutically acceptable salt f, wherein R1 is methyl, each R2 is methoxy; R3 is methyl; m is an integer of from 0 to 2; each R4 is independently selected from C1-C6 alkyl, R12O, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, R18C(O)O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, R21C(O)-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is ally substituted by one or more F; or two R4 attached to adjacent atoms of ring B form, er with the atoms to which they are attached, a 5- or 6-membered heterocyclic or carbocyclic ring, or a benzene ring; ring B is 5- or 6-membered aryl or ; provided that the compound is not: N-[(4-chlorophenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo[1,5-a]pyrimidinamine, N-(1,3-benzodioxolylmethyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-fluorophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, or yl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine.

6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein ring B is 6-membered heteroaryl, said heteroaryl being substituted by a moiety R4 in para position or said ring having a nitrogen atom in para position; or ring B is phenyl, said phenyl being substituted by a moiety R4 in para position.

7. The compound of claim 5 or 6, or a pharmaceutically acceptable salt thereof, n ring B is phenyl.

8. The compound claim 5, or a pharmaceutically able salt thereof, wherein ring B is 5- or 6-membered aryl.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein ring B is 6-membered heteroaryl.

10. The compound of claim 9, or a pharmaceutically able salt thereof, wherein ring B is 6-membered heteroaryl, said heteroaryl being substituted by a moiety R4 in para position or said heteroaryl having a en atom in para position.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein ring B is 4-pyridyl.

12. The compound of any one of claims 5 to 11, or a pharmaceutically able salt thereof, wherein each R4 is independently ed from C1-C6 alkyl, R12O, and halogen.

13. A compound according to claim 5, selected from 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[[4-(trifluoromethyl)phenyl]methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[4-(trifluoromethyl)phenyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]pyrazolo[1,5- a]pyrimidinamine, N-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]acetamide, 3-(3,4-dimethoxyphenyl)-N-[(4-dimethylaminophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(6-methoxypyridyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, N-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]methanesulfonamide, 4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenol, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(3-methylsulfonylphenyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(1-oxidopyridiniumyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(4-methylsulfonylphenyl)methyl]pyrazolo[1,5- midinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[2-(2-pyridyl)ethyl]pyrazolo[1,5-a]pyrimidin amine, N-[(4-tert-butylphenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(2-methylpyrimidinyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[2-(2-thienyl)ethyl]pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[2-(4-pyridyl)ethyl]pyrazolo[1,5-a]pyrimidin amine, -dimethoxyphenyl)-2,5-dimethyl-N-pyrazinyl-pyrazolo[1,5-a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-indanyl-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(6-methylpyridyl)methyl]pyrazolo[1,5- a]pyrimidinamine, N-[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinyl]methyl-thiazol- 2-amine, 1-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]ethanone, N-[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinyl]isoxazolamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(1-naphthylmethyl)pyrazolo[1,5-a]pyrimidin amine, and 4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]benzenesulfonamide, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition sing a compound according to any one of the claims 5 to 13, and optionally a pharmaceutically acceptable excipient.

15. The use of a composition according to any one of claims 1 to 4 or claim 14, or the compound according to any one of claims 5 to 13, in the cture of a medicament for the treatment of a viral infection.

16. The use according to claim 15, wherein the viral infection is an RNA viral infection.

17. The use of a compound of formula (Ie) or a pharmaceutically acceptable salt thereof, wherein R1 is methyl, each R2 is methoxy; R3 is methyl; m is an integer of from 0 to 2; each R4 is ndently selected from C1-C6 alkyl, R12O, halogen, R13R14NC(O)-, R16C(O)N(R15)-, R17OC(O)-, )O-, R19S(O)2-, R20S(O)2N(H)-, NH2S(O)2-, R21C(O)-, N(R22)(R23)-, and -O-; R12, R13, R14, R15, R22, and R23 are independently selected from H and C1-C6 alkyl, R16, R17, R18, R19, R20, and R21 are independently selected from C1-6 alkyl; any alkyl is optionally substituted by one or more F; or two R4 attached to adjacent atoms of ring B form, er with the atoms to which they are attached, a 5- or 6-membered heterocyclic or carbocyclic ring, or a benzene ring; ring B is 5- or 6-membered heteroaryl or phenyl; in the manufacture of a medicament for the treatment of an RNA viral infection.

18. The use according to claim 17, wherein the compound is ed from N-[(4-chlorophenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- midinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-methoxyphenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(p-tolylmethyl)pyrazolo[1,5-a]pyrimidinamine, N-(1,3-benzodioxolylmethyl)(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- midinamine, 3-(3,4-dimethoxyphenyl)-N-[(4-fluorophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(2-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, N-benzyl(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[[4-(trifluoromethyl)phenyl]methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(4-pyridylmethyl)pyrazolo[1,5-a]pyrimidin amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[[4-(trifluoromethoxy)phenyl]methyl]pyrazolo[1,5- a]pyrimidinamine, N-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]acetamide, 3-(3,4-dimethoxyphenyl)-N-[(4-dimethylaminophenyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-N-[(6-methoxypyridyl)methyl]-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, N-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]methanesulfonamide, 4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenol, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(3-methylsulfonylphenyl)methyl]pyrazolo[1,5- a]pyrimidinamine, -dimethoxyphenyl)-2,5-dimethyl-N-[(1-oxidopyridiniumyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(4-methylsulfonylphenyl)methyl]pyrazolo[1,5- a]pyrimidinamine, N-[(4-tert-butylphenyl)methyl](3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(2-methylpyrimidinyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-[(6-methylpyridyl)methyl]pyrazolo[1,5- a]pyrimidinamine, 1-[4-[[[3-(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]phenyl]ethanone, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N-(1-naphthylmethyl)pyrazolo[1,5-a]pyrimidin amine, and -(3,4-dimethoxyphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin yl]amino]methyl]benzenesulfonamide.

19. The use according to claim 17 or 18, wherein the RNA viral infection is a picornaviral infection.

20. A pharmaceutical composition according to claim 1, substantially as herein described or ified.

21. A compound according to claim 5, substantially as herein described or exemplified.

22. A pharmaceutical composition according to claim 14, substantially as herein described or exemplified.

23. A use according to claim 15, substantially as herein described or exemplified.

24. A use according to claim 17, substantially as herein bed or exemplified.